أبيليفاي

0

أبيليفاي

الاسم العام: aripiprazole
شكل الجرعة: قرص ، محلول فموي ، قرص متفكك شفويا ، حقن

على هذه الصفحة
  • تحذير محاصر
  • المؤشرات والاستخدام
  • الجرعة والإدارة
  • الجرعات ونقاط القوة
  • موانع الاستعمال
  • المحاذير والإحتياطات
  • ردود الفعل السلبية / الآثار الجانبية
  • تفاعل الأدوية
  • استخدم في مجموعات سكانية معينة
  • تعاطي المخدرات والاعتماد عليها
  • جرعة مفرطة
  • وصف
  • علم الصيدلة السريرية
  • علم السموم غير السريري
  • الدراسات السريرية
  • كيفية التزويد / التخزين والتداول
  • معلومات إرشاد المرضى

وسعت

تحذير: زيادة معدل الوفيات لدى كبار السن من المرضى الذين يعانون من الذهان المرتبط بالخرف والأفكار والسلوكيات الانتحارية مع الأدوية المضادة للاكتئاب

المرضى المسنون الذين يعانون من الذهان المرتبط بالخرف الذين يعالجون بالأدوية المضادة للذهان هم في خطر متزايد للوفاة. Abilify غير معتمد لعلاج المرضى الذين يعانون من الذهان المرتبط بالخرف [see Warnings and Precautions (5.1)] .

زادت مضادات الاكتئاب من خطر الأفكار والسلوك الانتحاري لدى الأطفال والمراهقين والشباب في دراسات قصيرة المدى. لم تظهر هذه الدراسات زيادة في خطر الأفكار والسلوك الانتحاري مع استخدام مضادات الاكتئاب في المرضى فوق سن 24 ؛ كان هناك انخفاض في خطر استخدام مضادات الاكتئاب في المرضى الذين تتراوح أعمارهم بين 65 وما فوق [see Warnings and Precautions (5.3)] .

في المرضى من جميع الأعمار الذين بدأوا في العلاج بمضادات الاكتئاب ، راقب عن كثب للتدهور ، ولظهور الأفكار والسلوكيات الانتحارية. نصح العائلات ومقدمي الرعاية بالحاجة إلى المراقبة الوثيقة والتواصل مع الواصف [see Warnings and Precautions (5.3)] .

مؤشرات واستخدام Abilify

يشار إلى Abilify Oral Tablets ، أقراص التفكك الفموي ، محلول فموي لعلاج:

  • فصام [see Clinical Studies (14.1)]
  • العلاج الحاد للنوبات الهوسية والمختلطة المرتبطة باضطراب ثنائي القطب الأول [see Clinical Studies (14.2)]
  • العلاج المساعد لاضطراب اكتئابي كبير [see Clinical Studies (14.3)]
  • التهيج المرتبط باضطراب التوحد [see Clinical Studies (14.4)]
  • علاج اضطراب توريت [see Clinical Studies (14.5)]

يوصف Abilify Solution لعلاج:

  • الانفعالات المرتبطة بالفصام أو الهوس ثنائي القطب [see Clinical Studies (14.6)]

Abilify الجرعة والإدارة

فصام

الكبار

جرعة البدء والهدف الموصى بها لـ Abilify هي 10 أو 15 مجم / يوم تدار على جدول مرة واحدة في اليوم دون اعتبار للوجبات. تم تقييم Abilify بشكل منهجي وتبين أنه فعال في نطاق جرعة من 10 إلى 30 مجم / يوم ، عند إعطائه كصيغة قرص ؛ ومع ذلك ، فإن الجرعات التي تزيد عن 10 أو 15 ملغ / يوم لم تكن أكثر فعالية من 10 أو 15 ملغ / يوم. بشكل عام ، يجب عدم زيادة الجرعة قبل أسبوعين ، وهو الوقت اللازم لتحقيق حالة مستقرة [see Clinical Studies (14.1)] .

علاج الصيانة: تم إثبات الحفاظ على الفعالية في مرض انفصام الشخصية في تجربة تشمل مرضى يعانون من مرض انفصام الشخصية الذين كانوا مستقرين من أعراض مضادات الذهان الأخرى لمدة 3 أشهر أو أكثر. تم إيقاف هؤلاء المرضى من تلك الأدوية وعشوائية إما Abilify 15 ملغ / يوم أو وهمي ، ولوحظوا من أجل الانتكاس [see Clinical Studies (14.1)] . يجب إعادة تقييم المرضى بشكل دوري لتحديد الحاجة المستمرة لعلاج الصيانة.

المراهقون

الجرعة المستهدفة الموصى بها من أبيليفاي 10 ملغ / يوم. تم دراسة Aripiprazole في المرضى المراهقين الذين تتراوح أعمارهم بين 13 و 17 سنة المصابين بالفصام بجرعات يومية من 10 ملغ و 30 ملغ. كانت الجرعة اليومية الأولية لصيغة الأقراص في هؤلاء المرضى 2 ملغ ، والتي تم معايرتها إلى 5 ملغ بعد يومين وإلى الجرعة المستهدفة 10 ملغ بعد يومين إضافيين. يجب إعطاء الزيادات اللاحقة في الجرعة بزيادات 5 ملغ. لم يثبت أن جرعة 30 ملغ / يوم أكثر فعالية من جرعة 10 ملغ / يوم. يمكن إعطاء أبيليفاي دون اعتبار للوجبات [see Clinical Studies (14.1)] . يجب إعادة تقييم المرضى بشكل دوري لتحديد الحاجة إلى علاج الصيانة.

التحول من مضادات الذهان الأخرى

لا توجد بيانات مجمعة بشكل منهجي للتعامل بشكل محدد مع تبديل المرضى المصابين بالفصام من مضادات الذهان الأخرى إلى أبيليفاي أو فيما يتعلق بالإعطاء المتزامن مع مضادات الذهان الأخرى. في حين أن التوقف الفوري عن العلاج السابق بمضادات الذهان قد يكون مقبولًا لدى بعض المرضى المصابين بالفصام ، فقد يكون التوقف التدريجي أكثر ملاءمة للآخرين. في جميع الحالات ، يجب تقليل فترة التداخل المضاد للذهان.

اضطراب ثنائي القطب الأول

العلاج الحاد لنوبات الهوس والمختلط

البالغين: جرعة البداية الموصى بها للبالغين هي 15 مجم تعطى مرة واحدة يوميًا كعلاج وحيد و 10 مجم إلى 15 مجم تعطى مرة واحدة يوميًا كعلاج مساعد مع الليثيوم أو الفالبروات. يمكن إعطاء Abilify دون اعتبار للوجبات. الجرعة المستهدفة الموصى بها من أبيليفاي هي 15 ملغ / يوم كعلاج أحادي أو كعلاج مساعد مع الليثيوم أو الفالبروات. يمكن زيادة الجرعة إلى 30 ملغ / يوم بناءً على الاستجابة السريرية. لم يتم تقييم سلامة الجرعات فوق 30 ملغ / يوم في التجارب السريرية.

طب الأطفال: جرعة البدء الموصى بها في مرضى الأطفال (10 إلى 17 سنة) كعلاج وحيد هي 2 ملغ / يوم ، مع معايرة إلى 5 ملغ / يوم بعد يومين ، وجرعة مستهدفة تبلغ 10 ملغ / يوم بعد يومين إضافيين. الجرعات الموصى بها كعلاج مساعد للليثيوم أو الفالبروات هي نفسها. يجب إعطاء الزيادات اللاحقة للجرعة ، إذا لزم الأمر ، بزيادات 5 ملغ / يوم. يمكن إعطاء Abilify دون اعتبار للوجبات [see Clinical Studies (14.2)] .

العلاج المساعد لاضطراب اكتئابي كبير

الكبار

جرعة البدء الموصى بها لـ Abilify كعلاج مساعد للمرضى الذين يتناولون بالفعل مضادات الاكتئاب هي 2-5 ملغ / يوم. نطاق الجرعة الموصى به هو 2 إلى 15 ملغ / يوم. يجب أن تحدث تعديلات الجرعة حتى 5 ملغ / يوم تدريجيًا ، على فترات لا تقل عن أسبوع واحد [see Clinical Studies (14.3)] . يجب إعادة تقييم المرضى بشكل دوري لتحديد الحاجة المستمرة لعلاج الصيانة.

التهيج المرتبط باضطراب التوحد

مرضى الأطفال (6 إلى 17 سنة)

نطاق الجرعة الموصى به لعلاج مرضى الأطفال الذين يعانون من التهيج المرتبط باضطراب التوحد هو 5 إلى 15 ملغ / يوم.

يجب البدء بالجرعات عند 2 ملغ / يوم. يجب زيادة الجرعة إلى 5 ملغ / يوم ، مع الزيادات اللاحقة إلى 10 أو 15 ملغ / يوم إذا لزم الأمر. يجب أن تحدث تعديلات الجرعة حتى 5 ملغ / يوم تدريجيًا ، على فترات لا تقل عن أسبوع واحد [see Clinical Studies (14.4)] . يجب إعادة تقييم المرضى بشكل دوري لتحديد الحاجة المستمرة لعلاج الصيانة.

اضطراب توريت

مرضى الأطفال (6 إلى 18 سنة)

نطاق الجرعة الموصى به لاضطراب توريت هو 5 إلى 20 ملغ / يوم.

بالنسبة للمرضى الذين يقل وزنهم عن 50 كجم ، يجب البدء بالجرعات عند 2 مجم / يوم بجرعة مستهدفة تبلغ 5 مجم / يوم بعد يومين. يمكن زيادة الجرعة إلى 10 ملغ / يوم في المرضى الذين لا يحققون السيطرة المثلى على التشنجات اللاإرادية. يجب أن تحدث تعديلات الجرعة تدريجياً على فترات لا تقل عن أسبوع واحد.

بالنسبة للمرضى الذين يزنون 50 كجم أو أكثر ، يجب البدء بالجرعات عند 2 مجم / يوم لمدة يومين ، ثم زيادتها إلى 5 مجم / يوم لمدة 5 أيام ، بجرعة مستهدفة تبلغ 10 مجم / يوم في اليوم 8. يمكن أن تكون الجرعة زيادة تصل إلى 20 ملغ / يوم للمرضى الذين لا يحققون السيطرة المثلى على التشنجات اللاإرادية. يجب أن تحدث تعديلات الجرعة تدريجياً بزيادات 5 ملغ / يوم على فترات لا تقل عن أسبوع واحد. [See Clinical Studies (14.5)].

يجب إعادة تقييم المرضى بشكل دوري لتحديد الحاجة المستمرة لعلاج الصيانة.

الانفعالات المرتبطة بالفصام أو الهوس ثنائي القطب (الحقن العضلي)

الكبار

الجرعة الموصى بها لهؤلاء المرضى هي 9.75 مجم. نطاق الجرعة الموصى به هو 5.25 إلى 15 ملغ. لم تظهر فائدة إضافية لـ 15 مجم مقارنة بـ 9.75 مجم. يمكن أخذ جرعة أقل من 5.25 ملغ عندما تبرر العوامل السريرية. إذا استمر التحريض على جرعة ثانية بعد الجرعة الأولية ، فيمكن إعطاء جرعات تراكمية تصل إلى ما مجموعه 30 ملغ / يوم. ومع ذلك ، لم يتم تقييم فعالية الجرعات المتكررة من حقن أبيليفاي في المرضى المهتاجين بشكل منهجي في التجارب السريرية الخاضعة للرقابة. لم يتم تقييم سلامة الجرعات اليومية الإجمالية التي تزيد عن 30 مجم أو الحقن بشكل متكرر أكثر من كل ساعتين بشكل كافٍ في التجارب السريرية [see Clinical Studies (14.6)] .

إذا تم تحديد علاج أبيليفاي المستمر سريريًا ، فيجب أن يحل أبيليفاي الفموي في نطاق من 10 إلى 30 مجم / يوم محل حقن أبيليفاي في أقرب وقت ممكن [see Dosage and Administration (2.1 and 2.2)] .

إدارة حقن أبيليفاي

لإدارة Abilify Injection ، ارسم الحجم المطلوب من المحلول في المحقنة كما هو موضح في الجدول 1. تخلص من أي جزء غير مستخدم.

الجدول 1: توصيات جرعات الحقن Abilify

جرعة واحدةحجم الحل المطلوب
5.25 مجم0.7 مل
9.75 مجم1.3 مل
15 ملغ2 مل

Abilify Injection مخصص للاستخدام العضلي فقط. لا تدار عن طريق الوريد أو تحت الجلد. احقن ببطء ، في عمق كتلة العضلات.

يجب فحص منتجات الأدوية الوريدية بصريًا بحثًا عن الجسيمات وتغير اللون قبل الإعطاء ، كلما سمح المحلول والحاوية.

تعديلات الجرعة لاعتبارات السيتوكروم P450

يوصى بتعديل الجرعة في المرضى المعروفين بالمستقلبات الضعيفة CYP2D6 وفي المرضى الذين يتناولون مثبطات CYP3A4 المصاحبة أو مثبطات CYP2D6 أو محفزات CYP3A4 القوية (انظر الجدول 2). عندما يتم سحب الدواء المدمر من العلاج المركب ، يجب تعديل جرعة أبيليفاي إلى مستواها الأصلي. عندما يتم سحب محفز CYP3A4 المعتمد على الكوميدوين ، يجب تخفيض جرعة أبيليفاي إلى المستوى الأصلي على مدى أسبوع إلى أسبوعين. المرضى الذين قد يتلقون مزيجًا من مثبطات قوية ومتوسطة وضعيفة لـ CYP3A4 و CYP2D6 (على سبيل المثال ، مثبط CYP3A4 قوي ومثبط CYP2D6 معتدل أو مثبط CYP3A4 معتدل مع مثبط CYP2D6 معتدل) ، يمكن تخفيض الجرعات إلى واحد – ربع (25٪) من الجرعة المعتادة مبدئيًا ثم يتم تعديلها لتحقيق استجابة سريرية مواتية.

الجدول 2: تعديلات الجرعات من أجل Abilify في المرضى المعروفين CYP2D6 سوء التمثيل الغذائي والمرضى الذين يتناولون مثبطات CYP2D6 المصاحبة ، ومثبطات 3A4 ، و / أو محفزات CYP3A4

العواملتعديلات الجرعة لأبيليفى
المعروف CYP2D6 ضعف التمثيل الغذائيأعط نصف الجرعة المعتادة
المعروف CYP2D6 ضعف التمثيل الغذائي أخذ مثبطات CYP3A4 المصاحبة القوية (على سبيل المثال ، إيتراكونازول ، كلاريثروميسين)أعط ربع الجرعة المعتادة
CYP2D6 قوي (على سبيل المثال ، الكينيدين ، فلوكستين ، باروكستين) أو مثبطات CYP3A4 (على سبيل المثال ، إيتراكونازول ، كلاريثروميسين)أعط نصف الجرعة المعتادة
مثبطات CYP2D6 و CYP3A4 القويةأعط ربع الجرعة المعتادة
محفزات CYP3A4 القوية (على سبيل المثال ، كاربامازيبين ، ريفامبين)مضاعفة الجرعة المعتادة خلال أسبوع إلى أسبوعين

عند إعطاء أبيليفاي المساعد للمرضى الذين يعانون من اضطراب اكتئابي رئيسي ، يجب إعطاء أبيليفاي دون تعديل الجرعة على النحو المحدد في الجرعة والإدارة (2.3).

جرعات محلول عن طريق الفم

يمكن استبدال المحلول الفموي بأقراص على أساس ملغم لكل ملغ حتى مستوى جرعة 25 ملغ. يجب أن يتلقى المرضى الذين يتناولون 30 مجم 25 قرصًا 25 مجم من المحلول [see Clinical Pharmacology (12.3)] .

جرعات أقراص التفكك الشفوي

الجرعات لأبيليفاي أقراص التفكك عن طريق الفم هي نفسها بالنسبة للأقراص الفموية [see Dosage and Administration (2.1, 2.2, 2.3, and 2.4)] .

الجرعات ونقاط القوة

تتوفر أقراص Abilify ® (aripiprazole) كما هو موضح في الجدول 3.

الجدول 3: Abilify العروض التقديمية اللوحية

قوة الجهاز اللوحيلون / شكل الكمبيوتر اللوحيعلامات اللوحي
2 ملغأخضر
مستطيل معدل
“A-006” و “2”
5 ملغأزرق
مستطيل معدل
“A-007” و “5”
10 ملغزهري
مستطيل معدل
“A-008” و “10”
15 ملغالأصفر
مستدير
“A-009” و “15”
20 ملغأبيض
مستدير
“A-010” و “20”
30 ملغزهري
مستدير
“A-011” و “30”

Abilify DISCMELT ® (aripiprazole) أقراص التفكك الشفوية متوفرة كما هو موضح في الجدول 4.

الجدول 4: Abilify DISCMELT العروض التقديمية اللوحية المتحللة شفويا

قوة الجهاز اللوحيلون / شكل الكمبيوتر اللوحيعلامات اللوحي
10 ملغالوردي (مع بقع متناثرة)
مستدير
“A” و “640”
“10”
15 ملغالأصفر (مع بقع متناثرة)
مستدير
“A” و “641”
“15”

Abilify ® (aripiprazole) محلول فموي (1 ملجم / مل) هو محلول شفاف عديم اللون إلى أصفر فاتح ، يتم توفيره في زجاجات مقاومة للأطفال مع كوب جرعات فموية معايرة.

Abilify ® (aripiprazole) حقن للاستخدام العضلي هو حل واضح عديم اللون متاح كمحلول جاهز للاستخدام 9.75 مجم / 1.3 مل (7.5 مجم / مل) في قوارير زجاجية شفافة من النوع 1.

موانع الاستعمال

يمنع استخدام Abilify في المرضى الذين لديهم تاريخ من تفاعلات فرط الحساسية للأريبيبرازول. تراوحت ردود الفعل بين الحكة / الشرى إلى الحساسية المفرطة [see Adverse Reactions (6.2)] .

المحاذير والإحتياطات

زيادة معدل الوفيات لدى المرضى المسنين المصابين بالذهان المرتبط بالخرف

زيادة معدل الوفيات

المرضى المسنون الذين يعانون من الذهان المرتبط بالخرف الذين يعالجون بالأدوية المضادة للذهان هم في خطر متزايد للوفاة. Abilify (aripiprazole) غير معتمد لعلاج المرضى الذين يعانون من الذهان المرتبط بالخرف [see Boxed Warning] .

تجربة السلامة في المرضى المسنين المصابين بالذهان المرتبط بمرض الزهايمر

في ثلاثة ، 10 أسابيع ، دراسات تسيطر عليها وهمي لأبيليفاي في المرضى المسنين المصابين بالذهان المرتبط بمرض الزهايمر (ن = 938 ؛ متوسط ​​العمر: 82.4 سنة ؛ النطاق: 56 إلى 99 سنة) ، ردود الفعل السلبية التي تم الإبلاغ عنها عند حدوث من ≥3٪ وحالات أبيليفاي على الأقل ضعف تلك التي تم علاجها من الغفل [placebo 2%, Abilify 5%]، النعاس (بما في ذلك التخدير) [placebo 3%, Abilify 8%]، وسلس البول (في المقام الأول ، سلس البول) [placebo 1%, Abilify 5%]اللعاب المفرط [placebo 0%, Abilify 4%]والدوار [placebo 1%, Abilify 4%].

لم تثبت سلامة وفعالية Abilify في علاج المرضى الذين يعانون من الذهان المرتبط بالخرف. إذا اختار الواصف علاج هؤلاء المرضى الذين يعانون من أبيليفاي ، فقم بتقييم ظهور صعوبة في البلع أو النعاس المفرط ، مما قد يؤدي إلى الإصابة العرضية أو الطموح [see Boxed Warning] .

الأحداث الضائرة الوعائية الدماغية ، بما في ذلك السكتة الدماغية

في الدراسات السريرية التي تسيطر عليها وهمي (جرعتين مرنة ودراسة واحدة بجرعة ثابتة) للذهان المرتبط بالخرف ، كان هناك زيادة في حدوث الأحداث الضائرة الوعائية الدماغية (على سبيل المثال ، السكتة الدماغية ، نوبة نقص تروية عابرة) ، بما في ذلك الوفيات ، في المرضى الذين عولجوا أبيليفاي ( متوسط ​​العمر: 84 عامًا ؛ النطاق: 78 إلى 88 عامًا). في دراسة الجرعة الثابتة ، كانت هناك علاقة ذات دلالة إحصائية لاستجابة الجرعة للأحداث الضائرة الوعائية الدماغية في المرضى الذين عولجوا بأبيليفاي. Abilify غير معتمد لعلاج المرضى الذين يعانون من الذهان المرتبط بالخرف [see Boxed Warning] .

الأفكار والسلوكيات الانتحارية لدى الأطفال والمراهقين والشباب

قد يعاني المرضى الذين يعانون من اضطراب اكتئابي كبير (MDD) ، على حد سواء للبالغين والأطفال ، من تفاقم الاكتئاب و / أو ظهور التفكير والسلوك الانتحاري (الانتحار) أو تغييرات غير عادية في السلوك ، سواء كانوا يتناولون أدوية مضادة للاكتئاب أم لا ، وهذا قد تستمر المخاطر حتى تحدث مغفرة كبيرة. الانتحار هو خطر معروف للاكتئاب وبعض الاضطرابات النفسية الأخرى ، وهذه الاضطرابات نفسها هي أقوى المؤشرات على الانتحار. ومع ذلك ، كان هناك قلق طويل الأمد ، من أن مضادات الاكتئاب قد يكون لها دور في إحداث تفاقم الاكتئاب وظهور الانتحار في بعض المرضى خلال المراحل المبكرة من العلاج. أظهرت التحليلات المجمعة للتجارب قصيرة المدى التي تسيطر عليها وهمي للأدوية المضادة للاكتئاب (SSRIs وغيرها) أن هذه الأدوية تزيد من خطر التفكير والسلوك الانتحاريين (الانتحارية) لدى الأطفال والمراهقين والشباب (من 18 إلى 24 عامًا) مع MDD وغيرها من الاضطرابات النفسية. لم تظهر الدراسات قصيرة المدى زيادة في خطر الانتحار مع مضادات الاكتئاب مقارنة مع الدواء الوهمي لدى البالغين بعد سن 24 ؛ كان هناك انخفاض مع مضادات الاكتئاب مقارنة مع الدواء الوهمي لدى البالغين الذين تتراوح أعمارهم بين 65 وما فوق.

تضمنت التحليلات المجمعة لتجارب مضبوطة بالغفل في الأطفال والمراهقين المصابين بال MDD أو الوسواس القهري (OCD) أو غيرها من الاضطرابات النفسية ما مجموعه 24 تجربة قصيرة الأجل لـ 9 أدوية مضادة للاكتئاب في أكثر من 4400 مريض. تضمنت التحليلات المجمعة لتجارب مضبوطة بالغفل في البالغين الذين يعانون من اضطرابات MDD أو غيرها من الاضطرابات النفسية ما مجموعه 295 تجربة قصيرة المدى (متوسط ​​المدة شهرين) من 11 دواء مضاد للاكتئاب في أكثر من 77000 مريض. كان هناك اختلاف كبير في خطر الانتحار بين الأدوية ، ولكن هناك ميل نحو زيادة في المرضى الأصغر سنا لجميع الأدوية التي تمت دراستها تقريبًا. كانت هناك اختلافات في الاختطار المطلق للانتحار عبر المؤشرات المختلفة ، مع أعلى نسبة في MDD. ومع ذلك ، كانت اختلافات الاختطار (الدواء مقابل الدواء الوهمي) مستقرة نسبيًا داخل الطبقات العمرية وعبر المؤشرات. ترد اختلافات الاختطار هذه (اختلاف الدواء – الدواء الوهمي في عدد حالات الانتحار لكل 1000 مريض معالج) في الجدول 5.

الجدول 5:

الفئة العمريةالفرق بين الدواء الوهمي في عدد حالات الانتحار لكل 1000 مريض تمت معالجتهم
الزيادات بالمقارنة مع الدواء الوهمي
<1814 حالة إضافية
18 إلى 245 حالات إضافية
انخفاض مقابل الدواء الوهمي
25 إلى 64حالة واحدة أقل
≥656 حالات أقل

لم تحدث حالات انتحار في أي من تجارب الأطفال. كانت هناك حالات انتحار في تجارب البالغين ، لكن العدد لم يكن كافيًا للتوصل إلى أي استنتاج حول تأثير المخدرات على الانتحار.

من غير المعروف ما إذا كان خطر الانتحار يمتد إلى الاستخدام على المدى الطويل ، أي بعد عدة أشهر. ومع ذلك ، هناك أدلة كبيرة من تجارب الصيانة التي تسيطر عليها وهمي لدى البالغين الذين يعانون من الاكتئاب أن استخدام مضادات الاكتئاب يمكن أن يؤخر تكرار الاكتئاب.

يجب مراقبة جميع المرضى الذين يعالجون بمضادات الاكتئاب لأي إشارة يجب ملاحظتها بشكل مناسب وملاحظة عن كثب للتدهور السريري والانتحار والتغيرات غير المعتادة في السلوك ، خاصة خلال الأشهر القليلة الأولى من دورة العلاج الدوائي ، أو في أوقات تغيرات الجرعة ، إما يزيد أو نقصان.

تم الإبلاغ عن الأعراض التالية ، والقلق ، والإثارة ، ونوبات الهلع ، والأرق ، والتهيج ، والعداوة ، والعدوانية ، والاندفاع ، والعرق (الأرق الحركي النفسي) ، وهوس خفيف ، والهوس ، في المرضى البالغين والأطفال الذين يعالجون بمضادات الاكتئاب من أجل MDD وكذلك من أجل مؤشرات أخرى ، نفسية وغير نفسية. على الرغم من عدم وجود صلة سببية بين ظهور مثل هذه الأعراض وإما تفاقم الاكتئاب و / أو ظهور النبضات الانتحارية ، إلا أن هناك مخاوف من أن مثل هذه الأعراض قد تمثل سلعة للانتحار الناشئ.

ينبغي النظر في تغيير النظام العلاجي ، بما في ذلك ربما التوقف عن تناول الدواء ، في المرضى الذين يعانون من اكتئاب أسوأ باستمرار ، أو الذين يعانون من الانتحار أو الأعراض الناشئة التي قد تكون مقدمة لتفاقم الاكتئاب أو الانتحار ، خاصة إذا كانت هذه الأعراض شديدة أو مفاجئة في البداية ، أو لم تكن جزءًا من الأعراض التي تظهر على المريض.

يجب تنبيه أسر ومقدمي الرعاية للمرضى الذين يعالجون بمضادات الاكتئاب لاضطراب اكتئابي كبير أو مؤشرات أخرى ، نفسية وغير نفسية ، حول الحاجة إلى مراقبة المرضى لظهور التحريض والتهيج والتغيرات غير المعتادة في السلوك والأعراض الأخرى الموضحة أعلاه ، وكذلك ظهور الانتحار ، والإبلاغ عن هذه الأعراض على الفور لمقدمي الرعاية الصحية. يجب أن يشمل هذا الرصد المراقبة اليومية من قبل الأسر ومقدمي الرعاية. يجب كتابة الوصفات الطبية لأبيليفاي لأصغر كمية من الأقراص المتوافقة مع الإدارة الجيدة للمرضى ، من أجل تقليل مخاطر الجرعة الزائدة.

فحص مرضى الاضطراب ثنائي القطب: قد تكون النوبة الاكتئابية الرئيسية هي العرض الأولي للاضطراب ثنائي القطب. يعتقد بشكل عام (على الرغم من عدم إثبات ذلك في التجارب الخاضعة للرقابة) أن علاج مثل هذه الحلقة بمضاد للاكتئاب وحده قد يزيد من احتمال هطول نوبة مختلطة / هوس في المرضى المعرضين لخطر الاضطراب ثنائي القطب. ما إذا كان أي من الأعراض الموضحة أعلاه تمثل مثل هذا التحويل غير معروف. ومع ذلك ، قبل البدء في العلاج باستخدام مضاد للاكتئاب ، يجب فحص المرضى الذين يعانون من أعراض الاكتئاب بشكل كاف لتحديد ما إذا كانوا معرضين لخطر الاضطراب ثنائي القطب ؛ يجب أن يتضمن هذا الفحص تاريخًا نفسيًا مفصلاً ، بما في ذلك تاريخ عائلي من الانتحار والاضطراب ثنائي القطب والاكتئاب.

وتجدر الإشارة إلى أن أبيليفاي غير معتمد للاستخدام في علاج الاكتئاب لدى الأطفال.

المتلازمة الخبيثة للذهان (NMS)

قد يُشار إلى أحد أعراض الأعراض المميتة التي يُشار إليها أحيانًا باسم المتلازمة الخبيثة للذهان (NMS) مع إعطاء الأدوية المضادة للذهان ، بما في ذلك Abilify. حدثت حالات نادرة من NMS أثناء علاج Abilify في قاعدة البيانات السريرية في جميع أنحاء العالم. المظاهر السريرية لـ NMS هي فرط الحرارة ، وتصلب العضلات ، والحالة العقلية المتغيرة ، ودليل على عدم الاستقرار اللاإرادي (عدم انتظام النبض أو ضغط الدم ، عدم انتظام دقات القلب ، الحجاب الحاجز ، وخلل ضربات القلب). قد تشمل العلامات الإضافية ارتفاع فوسفوكيناز الكرياتين ، بيلة ميوغلوبينية (انحلال الربيدات) ، والفشل الكلوي الحاد.

التقييم التشخيصي للمرضى الذين يعانون من هذه المتلازمة معقد. عند الوصول إلى التشخيص ، من المهم استبعاد الحالات التي تتضمن فيها العروض السريرية مرضًا طبيًا خطيرًا (مثل الالتهاب الرئوي والعدوى الجهازية) وعلامات وأعراض خارج السبيل الهرمي غير المعالجة أو غير كافية (EPS). تشمل الاعتبارات الهامة الأخرى في التشخيص التفريقي السمية المركزية لمضادات الكولين ، وضربة الحرارة ، وحمى الدواء ، وأمراض الجهاز العصبي المركزي الأساسي.

يجب أن تتضمن إدارة NMS: 1) التوقف الفوري عن الأدوية المضادة للذهان والأدوية الأخرى غير الضرورية للعلاج المتزامن ؛ 2) علاج الأعراض المكثفة والمراقبة الطبية ؛ و 3) علاج أي مشاكل طبية خطيرة يصاحبها تتوفر علاجات محددة. لا يوجد اتفاق عام حول أنظمة علاج دوائية محددة ل NMS غير معقدة.

إذا كان المريض يحتاج إلى علاج بالعقاقير المضادة للذهان بعد الشفاء من NMS ، فيجب النظر بعناية في إعادة إدخال العلاج بالعقاقير. يجب مراقبة المريض بعناية ، حيث تم الإبلاغ عن تكرار NMS.

خلل الحركة المتأخر

قد تتطور متلازمة الحركات اللاإرادية التي لا رجعة فيها ، في المرضى الذين يعالجون بالأدوية المضادة للذهان. على الرغم من أن انتشار المتلازمة يبدو أنه أعلى بين كبار السن ، وخاصة النساء المسنات ، فمن المستحيل الاعتماد على تقديرات الانتشار للتنبؤ ، عند بدء العلاج بمضادات الذهان ، بالمرضى الذين من المحتمل أن يصابوا بالمتلازمة. من غير المعروف ما إذا كانت منتجات الأدوية المضادة للذهان تختلف في قدرتها على التسبب في خلل الحركة المتأخر ، فقد تتطور متلازمة الحركات اللاإرادية واللاإرادية في المرضى الذين يعالجون بالأدوية المضادة للذهان. على الرغم من أن انتشار المتلازمة يبدو أنه أعلى بين كبار السن ، وخاصة النساء المسنات ، فمن المستحيل الاعتماد على تقديرات الانتشار للتنبؤ ، عند بدء العلاج بمضادات الذهان ، بالمرضى الذين من المحتمل أن يصابوا بالمتلازمة. ما إذا كانت منتجات الأدوية المضادة للذهان تختلف في قدرتها على التسبب في خلل الحركة المتأخر غير معروف.

يُعتقد أن خطر الإصابة بخلل الحركة المتأخر واحتمالية أن يصبح لا رجعة فيه يزداد مع زيادة مدة العلاج والجرعة التراكمية الإجمالية للأدوية المضادة للذهان التي يتم إعطاؤها للمريض. ومع ذلك ، يمكن أن تتطور المتلازمة ، على الرغم من أنها أقل شيوعًا ، بعد فترات علاج قصيرة نسبيًا بجرعات منخفضة ، ويُعتقد أن خطر الإصابة بخلل الحركة المتأخر واحتمالية أن يصبح لا رجعة فيه يزداد مع مدة العلاج والجرعة التراكمية الإجمالية من الأدوية المضادة للذهان تدار لزيادة المريض. ومع ذلك ، يمكن أن تتطور المتلازمة ، على الرغم من أنها أقل شيوعًا ، بعد فترات علاج قصيرة نسبيًا بجرعات منخفضة.

قد يعطل خلل الحركة المتأخر جزئيًا أو كليًا إذا تم سحب العلاج بمضادات الذهان. العلاج المضاد للذهان ، في حد ذاته ، قد يقمع (أو يقمع جزئيًا) علامات وأعراض المتلازمة ، وبالتالي ، قد يخفي العملية الكامنة. إن تأثير قمع الأعراض على المسار الطويل للمتلازمة غير معروف.

بالنظر إلى هذه الاعتبارات ، يجب وصف Abilify بطريقة من المرجح أن تقلل من حدوث خلل الحركة المتأخر. بشكل عام ، يجب حجز العلاج بمضادات الذهان المزمنة للمرضى الذين يعانون من مرض مزمن (1) معروف باستجابته للأدوية المضادة للذهان و (2) الذين لا تتوفر لهم العلاجات البديلة الفعالة بنفس القدر ولكن الأقل خطورة. في المرضى الذين يحتاجون إلى علاج مزمن ، يجب البحث عن أصغر جرعة وأقصر مدة علاج تنتج استجابة سريرية مرضية. يجب إعادة تقييم الحاجة إلى العلاج المستمر بشكل دوري ، وبالنظر إلى هذه الاعتبارات ، يجب وصف Abilify بطريقة من المرجح أن تقلل من حدوث خلل الحركة المتأخر. بشكل عام ، يجب حجز العلاج بمضادات الذهان المزمنة للمرضى الذين يعانون من مرض مزمن (1) معروف باستجابته للأدوية المضادة للذهان و (2) الذين لا تتوفر لهم العلاجات البديلة الفعالة بنفس القدر ولكن الأقل خطورة. في المرضى الذين يحتاجون إلى علاج مزمن ، يجب البحث عن أصغر جرعة وأقصر مدة علاج تنتج استجابة سريرية مرضية. يجب إعادة تقييم الحاجة لاستمرار العلاج بشكل دوري.

إذا ظهرت علامات وأعراض خلل الحركة المتأخر في المريض عند أبيليفاي ، فيجب النظر في التوقف عن تناول الدواء. ومع ذلك ، قد يحتاج بعض المرضى إلى علاج Abilify على الرغم من وجود المتلازمة. إذا ظهرت علامات وأعراض خلل الحركة المتأخر في المريض عند Abilify ، فيجب النظر في التوقف عن تناول الدواء. ومع ذلك ، قد يحتاج بعض المرضى إلى علاج Abilify على الرغم من وجود المتلازمة.

التغييرات الأيضية

ارتبطت الأدوية المضادة للذهان غير التقليدية مع التغيرات الأيضية التي تشمل فرط سكر الدم / داء السكري ، شحوم الدم ، وزيادة وزن الجسم. في حين ثبت أن جميع الأدوية في الصف تنتج بعض التغيرات الأيضية ، فإن لكل دواء ملف تعريف خاص به للمخاطر.

فرط سكر الدم / داء السكري

تم الإبلاغ عن فرط سكر الدم ، في بعض الحالات الشديدة والمرتبطة بالحماض الكيتوني أو الغيبوبة المفرطة أو الموت ، في المرضى الذين عولجوا بمضادات الذهان غير التقليدية. كانت هناك تقارير عن فرط سكر الدم في المرضى الذين عولجوا بأبيليفاي [see Adverse Reactions (6.1, 6.2)] . إن تقييم العلاقة بين استخدام مضادات الذهان غير التقليدية وتشوهات الجلوكوز معقد بسبب إمكانية زيادة خطر الإصابة بمرض السكري في الخلفية لدى مرضى الفصام وزيادة معدل الإصابة بمرض السكري بين عامة السكان. بالنظر إلى هذه الإرباكات ، فإن العلاقة بين استخدام مضادات الذهان غير التقليدية والأحداث السلبية المرتبطة بسكر الدم غير مفهومة تمامًا. ومع ذلك ، تشير الدراسات الوبائية إلى زيادة خطر حدوث تفاعلات ضائرة ذات صلة بفرط سكر الدم لدى المرضى الذين يعالجون بمضادات الذهان غير التقليدية. لأنه لم يتم تسويق Abilify في وقت إجراء هذه الدراسات ، فمن غير المعروف ما إذا كان Abilify مرتبطًا بهذا الخطر المتزايد. لا تتوفر تقديرات مخاطر دقيقة لردود الفعل السلبية ذات الصلة بفرط سكر الدم لدى المرضى الذين عولجوا بمضادات الذهان غير التقليدية.

يجب مراقبة المرضى الذين لديهم تشخيص ثابت لمرض السكري الذين بدأوا في تناول مضادات الذهان غير التقليدية بانتظام لتفاقم السيطرة على الجلوكوز. يجب على المرضى الذين يعانون من عوامل خطر الإصابة بداء السكري (على سبيل المثال ، السمنة ، والتاريخ العائلي لمرض السكري) الذين يبدأون العلاج بمضادات الذهان غير التقليدية أن يخضعوا لاختبار سكر الدم الصائم في بداية العلاج وبشكل دوري أثناء العلاج. يجب مراقبة أي مريض يعالج بمضادات الذهان غير التقليدية لأعراض فرط سكر الدم بما في ذلك عطاش ، بوال ، عرق ، وضعف. يجب على المرضى الذين تظهر عليهم أعراض فرط سكر الدم أثناء العلاج بمضادات الذهان غير التقليدية الخضوع لاختبار سكر الدم الصائم. في بعض الحالات ، تم حل فرط سكر الدم عندما توقف مضادات الذهان غير التقليدية. ومع ذلك ، تطلب بعض المرضى استمرار العلاج من مرض السكري على الرغم من التوقف عن الدواء المشتبه فيه.

الكبار

في تحليل 13 تجربة علاج أحادية مضبوطة بالغفل ، في المقام الأول مع الفصام أو الاضطراب ثنائي القطب ، لم يكن متوسط ​​التغيير في جلوكوز الصيام في المرضى الذين عولجوا في أبيليفاي (+4.4 مجم / ديسيلتر ؛ متوسط ​​التعرض 25 يومًا ؛ N = 1057) بشكل ملحوظ يختلف عن المرضى الذين عولجوا بالغفل (+2.5 مجم / ديسيلتر ؛ متوسط ​​التعرض 22 يومًا ؛ N = 799). يوضح الجدول 6 نسبة المرضى الذين عولجوا أبيليفاي مع جلوكوز الصيام العادي والحدود عند خط الأساس (التعرض المتوسط ​​25 يومًا) الذين لديهم قياسات غلوكوز صيام عالية ناشئة عن العلاج مقارنة بالمرضى الذين عولجوا بالغفل (متوسط ​​التعرض 22 يومًا).

الجدول 6: التغيرات في جلوكوز الصيام من تجارب العلاج الأحادي التي تسيطر عليها وهمي في المرضى البالغين

تغيير الفئة (مرة واحدة على الأقل) من خط الأساسذراع العلاجن / ن٪
السكر الصائمعادي إلى مرتفع
(<100 ملجم / دل إلى to126 ملجم / دل)
أبيليفاي31/8223.8
الوهمي22/6053.6
حد أعلى إلى أعلى
(≥100 ملجم / دل و <126 ملجم / دل إلى ≥126 ملجم / دل)
أبيليفاي31/17617.6
الوهمي13/1429.2

في 24 أسبوعًا ، لم يكن متوسط ​​التغيير في جلوكوز الصيام لدى مرضى أبيليفاي مختلفًا بشكل ملحوظ عن المرضى الذين عولجوا بالغفل [+2.2 mg/dL (n=42) and +9.6 mg/dL (n=28), respectively].

لم يكن التغيير المتوسط ​​في الجلوكوز الصائم في مرضى علاج أبيليفي المساعد الذين يعانون من اضطراب اكتئابي كبير (+0.7 مجم / ديسيلتر ؛ متوسط ​​التعرض 42 يومًا ؛ N = 241) لا يختلف اختلافًا كبيرًا عن المرضى الذين عولجوا بالغفل (+0.8 مجم / ديسيلتر ؛ متوسط التعرض 42 يومًا ؛ N = 246). يوضح الجدول 7 نسبة المرضى البالغين الذين يعانون من تغيرات في مستويات الجلوكوز أثناء الصيام من تجربتين مساعدتين يتم التحكم فيهما بالغفل (متوسط ​​التعرض 42 يومًا) في المرضى الذين يعانون من اضطراب اكتئابي كبير.

الجدول 7: التغيرات في جلوكوز الصيام من التجارب المساعدة التي تسيطر عليها وهمي في المرضى البالغين الذين يعانون من اضطراب اكتئابي كبير

تغيير الفئة (مرة واحدة على الأقل) من خط الأساسذراع العلاجن / ن٪
السكر الصائمعادي إلى مرتفع
(<100 ملجم / دل إلى to126 ملجم / دل)
أبيليفاي2/2011.0
الوهمي2/2041.0
حد أعلى إلى أعلى
(≥100 ملجم / دل و <126 ملجم / دل إلى ≥126 ملجم / دل)
أبيليفاي4/3411.8
الوهمي3/378.1

الأطفال والمراهقون

في تحليل تجربتين مضبوطات بالغفل في المراهقين المصابين بمرض انفصام الشخصية (13 إلى 17 عامًا) ومرضى الأطفال الذين يعانون من اضطراب ثنائي القطب (10 إلى 17 عامًا) ، يعني التغير في الجلوكوز الصائم لدى مرضى أبيليفاي (+4.8 مجم / ديسيلتر) ؛ مع متوسط ​​تعرض يبلغ 43 يومًا ؛ N = 259) لم يكن مختلفًا بشكل ملحوظ عن المرضى الذين عولجوا بالغفل (+1.7 مجم / ديسيلتر ؛ مع تعرض متوسط ​​42 يومًا ؛ N = 123).

في تحليل تجربتين محكومتين بالغفل في مرضى الأطفال والمراهقين الذين يعانون من التهيج المرتبط باضطراب التوحد (6 إلى 17 عامًا) مع متوسط ​​التعرض لمدة 56 يومًا ، متوسط ​​التغير في الجلوكوز الصائم في المرضى الذين عولجوا أبيليفاي (–0.2 ملغ / ديسيلتر) ؛ N = 83) لم يكن مختلفًا بشكل ملحوظ عن المرضى الذين عولجوا بالغفل (–0.6 مجم / ديسيلتر ؛ N = 33).

في تحليل تجربتين محكومتين بالغفل في مرضى الأطفال والمراهقين الذين يعانون من اضطراب توريت (6 إلى 18 عامًا) مع تعرض متوسط ​​لمدة 57 يومًا ، فإن متوسط ​​التغير في الجلوكوز الصائم في المرضى الذين عولجوا أبيليفاي (0.79 مجم / ديسيلتر ، ن = 90 ) لا تختلف اختلافا كبيرا عن المرضى الذين عولجوا بالغفل (-1.66 ملغم / ديسيلتر ، ن = 58).

يوضح الجدول 8 نسبة المرضى الذين يعانون من تغيرات في مستويات الجلوكوز الصائم من فصام المراهقين المجمعين ومرضى ثنائي القطب الأطفال (متوسط ​​التعرض من 42 إلى 43 يومًا) ، من تجربتين محكوميتين بالغفل في مرضى الأطفال (6 إلى 17 سنة) مع التهيج المرتبط with autistic disorder (median exposure of 56 days), and from the two placebo-controlled trials in pediatric patients (6 to 18 year) with Tourette’s Disorder (median exposure 57 days).

Table 8: Changes in Fasting Glucose from Placebo-Controlled Trials in Pediatric and Adolescent Patients

Category Change (at least once) from BaselineIndicationTreatment Armn/N%

Fasting Glucose
Normal to High
(<100 mg/dL to ≥126 mg/dL)

Pooled Schizophrenia and Bipolar DisorderAbilify2/2360.8
Placebo2/1101.8
Irritability Associated with Autistic DisorderAbilify0/730
Placebo0/320
Tourette’s DisorderAbilify3/883.4
Placebo1/581.7

Fasting Glucose
Borderline to High
(≥100 mg/dL and <126 mg/dL to ≥126 mg/dL)

Pooled Schizophrenia and Bipolar DisorderAbilify1/224.5
Placebo0/120
Irritability Associated with Autistic DisorderAbilify0/90
Placebo0/10
Tourette’s DisorderAbilify0/110
Placebo0/40

At 12 weeks in the pooled adolescent schizophrenia and pediatric bipolar disorder trials, the mean change in fasting glucose in Abilify-treated patients was not significantly different than in placebo-treated patients [+2.4 mg/dL (n=81) and +0.1 mg/dL (n=15), respectively].

Dyslipidemia

Undesirable alterations in lipids have been observed in patients treated with atypical antipsychotics.

There were no significant differences between Abilify- and placebo-treated patients in the proportion with changes from normal to clinically significant levels for fasting/nonfasting total cholesterol, fasting triglycerides, fasting LDLs, and fasting/nonfasting HDLs. Analyses of patients with at least 12 or 24 weeks of exposure were limited by small numbers of patients.

الكبار

Table 9 shows the proportion of adult patients, primarily from pooled schizophrenia and bipolar disorder monotherapy placebo-controlled trials, with changes in total cholesterol (pooled from 17 trials; median exposure 21 to 25 days), fasting triglycerides (pooled from eight trials; median exposure 42 days), fasting LDL cholesterol (pooled from eight trials; median exposure 39 to 45 days, except for placebo-treated patients with baseline normal fasting LDL measurements, who had median treatment exposure of 24 days) and HDL cholesterol (pooled from nine trials; median exposure 40 to 42 days).

Table 9: Changes in Blood Lipid Parameters from Placebo-Controlled Monotherapy Trials in Adults

Treatment Armn/N%

Total Cholesterol
Normal to High
(<200 mg/dL to ≥240 mg/dL)

Abilify34/13572.5
Placebo27/9732.8

Fasting Triglycerides
Normal to High
(<150 mg/dL to ≥200 mg/dL)

Abilify40/5397.4
Placebo30/4317.0

Fasting LDL Cholesterol
Normal to High
(<100 mg/dL to ≥160 mg/dL)

Abilify2/3320.6
Placebo2/2680.7

HDL Cholesterol
Normal to Low
(≥40 mg/dL to <40 mg/dL)

Abilify121/106611.4
Placebo99/79412.5

In monotherapy trials in adults, the proportion of patients at 12 weeks and 24 weeks with changes from Normal to High in total cholesterol (fasting/nonfasting), fasting triglycerides, and fasting LDL cholesterol were similar between Abilify- and placebo-treated patients: at 12 weeks, Total Cholesterol (fasting/nonfasting), 1/71 (1.4%) vs. 3/74 (4.1%); Fasting Triglycerides, 8/62 (12.9%) vs. 5/37 (13.5%); Fasting LDL Cholesterol, 0/34 (0%) vs. 1/25 (4.0%), respectively; and at 24 weeks, Total Cholesterol (fasting/nonfasting), 1/42 (2.4%) vs. 3/37 (8.1%); Fasting Triglycerides, 5/34 (14.7%) vs. 5/20 (25%); Fasting LDL Cholesterol, 0/22 (0%) vs. 1/18 (5.6%), respectively.

Table 10 shows the proportion of patients with changes in total cholesterol (fasting/nonfasting), fasting triglycerides, fasting LDL cholesterol, and HDL cholesterol from two placebo-controlled adjunctive trials in adult patients with major depressive disorder (median exposure 42 days).

Table 10: Changes in Blood Lipid Parameters from Placebo-Controlled Adjunctive Trials in Adult Patients with Major Depressive Disorder

Treatment Armn/N%

Total Cholesterol
Normal to High
(<200 mg/dL to ≥240 mg/dL)

Abilify3/1392.2
Placebo7/1355.2

Fasting Triglycerides
Normal to High
(<150 mg/dL to ≥200 mg/dL)

Abilify14/1459.7
Placebo6/1474.1

Fasting LDL Cholesterol
Normal to High
(<100 mg/dL to ≥160 mg/dL)

Abilify0/540
Placebo0/730

HDL Cholesterol
Normal to Low
(≥40 mg/dL to <40 mg/dL)

Abilify17/3185.3
Placebo10/2863.5

Pediatric Patients and Adolescents

Table 11 shows the proportion of adolescents with schizophrenia (13 to 17 years) and pediatric patients with bipolar disorder (10 to 17 years) with changes in total cholesterol and HDL cholesterol (pooled from two placebo-controlled trials; median exposure 42 to 43 days) and fasting triglycerides (pooled from two placebo-controlled trials; median exposure 42 to 44 days).

Table 11: Changes in Blood Lipid Parameters from Placebo-Controlled Monotherapy Trials in Pediatric and Adolescent Patients in Schizophrenia and Bipolar Disorder

Treatment Armn/N%

Total Cholesterol
Normal to High
(<170 mg/dL to ≥200 mg/dL)

Abilify3/2201.4
Placebo0/1160

Fasting Triglycerides
Normal to High
(<150 mg/dL to ≥200 mg/dL)

Abilify7/1873.7
Placebo4/854.7

HDL Cholesterol
Normal to Low
(≥40 mg/dL to <40 mg/dL)

Abilify27/23611.4
Placebo22/10920.2

In monotherapy trials of adolescents with schizophrenia and pediatric patients with bipolar disorder, the proportion of patients at 12 weeks and 24 weeks with changes from Normal to High in total cholesterol (fasting/nonfasting), fasting triglycerides, and fasting LDL cholesterol were similar between Abilify- and placebo-treated patients: at 12 weeks, Total Cholesterol (fasting/nonfasting), 0/57 (0%) vs. 0/15 (0%); Fasting Triglycerides, 2/72 (2.8%) vs. 1/14 (7.1%), respectively; and at 24 weeks, Total Cholesterol (fasting/nonfasting), 0/36 (0%) vs. 0/12 (0%); Fasting Triglycerides, 1/47 (2.1%) vs. 1/10 (10.0%), respectively.

Table 12 shows the proportion of patients with changes in total cholesterol (fasting/nonfasting) and fasting triglycerides (median exposure 56 days) and HDL cholesterol (median exposure 55 to 56 days) from two placebo-controlled trials in pediatric patients (6 to 17 years) with irritability associated with autistic disorder.

Table 12: Changes in Blood Lipid Parameters from Placebo-Controlled Trials in Pediatric Patients with Autistic Disorder

Treatment Armn/N%

Total Cholesterol
Normal to High
(<170 mg/dL to ≥200 mg/dL)

Abilify1/951.1
Placebo0/340

Fasting Triglycerides
Normal to High
(<150 mg/dL to ≥200 mg/dL)

Abilify0/750
Placebo0/300

HDL Cholesterol
Normal to Low
(≥40 mg/dL to <40 mg/dL)

Abilify9/1078.4
Placebo5/4910.2

Table 13 shows the proportion of patients with changes in total cholesterol (fasting/nonfasting) and fasting triglycerides (median exposure 57 days) and HDL cholesterol (median exposure 57 days) from two placebo-controlled trials in pediatric patients (6 to 18 years) with Tourette’s Disorder.

Table 13: Changes in Blood Lipid Parameters from Placebo-Controlled Trials in Pediatric Patients with Tourette’s Disorder

Treatment Armn/N%
Total Cholesterol
Normal to High
(<170 mg/dL to ≥200 mg/dL)
Abilify1/851.2
Placebo0/460
Fasting Triglycerides
Normal to High
(<150 mg/dL to ≥200 mg/dL)
Abilify5/945.3
Placebo2/553.6
HDL Cholesterol
Normal to Low
(≥40 mg/dL to <40 mg/dL)
Abilify4/1083.7
Placebo2/673.0

Weight Gain

Weight gain has been observed with atypical antipsychotic use. Clinical monitoring of weight is recommended.

الكبار

In an analysis of 13 placebo-controlled monotherapy trials, primarily from pooled schizophrenia and bipolar disorder, with a median exposure of 21 to 25 days, the mean change in body weight in Abilify-treated patients was +0.3 kg (N=1673) compared to –0.1 kg (N=1100) in placebo-controlled patients. At 24 weeks, the mean change from baseline in body weight in Abilify-treated patients was –1.5 kg (n=73) compared to –0.2 kg (n=46) in placebo-treated patients.

In the trials adding Abilify to antidepressants, patients first received 8 weeks of antidepressant treatment followed by 6 weeks of adjunctive Abilify or placebo in addition to their ongoing antidepressant treatment. The mean change in body weight in patients receiving adjunctive Abilify was +1.7 kg (N=347) compared to +0.4 kg (N=330) in patients receiving adjunctive placebo.

Table 14 shows the percentage of adult patients with weight gain ≥7% of body weight by indication.

Table 14: Percentage of Patients from Placebo-Controlled Trials in Adult Patients with Weight Gain ≥7% of Body Weight

IndicationTreatment ArmNPatients
n (%)

*
4 to 6 weeks duration

3 weeks duration.

6 weeks duration.

Weight gain ≥7% of body weightSchizophrenia *Abilify85269 (8.1)
Placebo37912 (3.2)
Bipolar Mania †Abilify71916 (2.2)
Placebo59816 (2.7)
Major Depressive Disorder
(Adjunctive Therapy) ‡
Abilify34718 (5.2)
Placebo3302 (0.6)

Pediatric Patients and Adolescents

In an analysis of two placebo-controlled trials in adolescents with schizophrenia (13 to 17 years) and pediatric patients with bipolar disorder (10 to 17 years) with median exposure of 42 to 43 days, the mean change in body weight in Abilify-treated patients was +1.6 kg (N=381) compared to +0.3 kg (N=187) in placebo-treated patients. At 24 weeks, the mean change from baseline in body weight in Abilify-treated patients was +5.8 kg (n=62) compared to +1.4 kg (n=13) in placebo-treated patients.

In two short-term, placebo-controlled trials in patients (6 to 17 years) with irritability associated with autistic disorder with median exposure of 56 days, the mean change in body weight in Abilify-treated patients was +1.6 kg (n=209) compared to +0.4 kg (n=98) in placebo-treated patients.

In two short-term, placebo-controlled trials in patients (6 to 18 years) with Tourette’s Disorder with median exposure of 57 days, the mean change in body weight in Abilify-treated patients was +1.5 kg (n=105) compared to +0.4 kg (n=66) in placebo-treated patients.

Table 15 shows the percentage of pediatric and adolescent patients with weight gain ≥7% of body weight by indication.

Table 15: Percentage of Patients from Placebo-Controlled Monotherapy Trials in Pediatric and Adolescent Patients with Weight Gain ≥7% of Body Weight

IndicationTreatment ArmNPatients n (%)

*
4 to 6 weeks duration

8 weeks duration.

8 to 10 weeks duration.

Weight gain ≥7% of body weightPooled Schizophrenia and Bipolar Mania *Abilify38120 (5.2)
Placebo1873 (1.6)
Irritability Associated with Autistic Disorder †Abilify20955 (26.3)
Placebo987 (7.1)
Tourette’s Disorder ‡Abilify10521 (20.0)
Placebo665 (7.6)

In an open-label trial that enrolled patients from the two placebo-controlled trials of adolescents with schizophrenia (13 to 17 years) and pediatric patients with bipolar disorder (10 to 17 years), 73.2% of patients (238/325) completed 26 weeks of therapy with Abilify. After 26 weeks, 32.8% of patients gained ≥7% of their body weight, not adjusted for normal growth. To adjust for normal growth, z-scores were derived (measured in standard deviations [SD]), which normalize for the natural growth of pediatric patients and adolescents by comparisons to age- and gender-matched population standards. A z-score change <0.5 SD is considered not clinically significant. After 26 weeks, the mean change in z-score was 0.09 SD.

In an open-label trial that enrolled patients from two short-term, placebo-controlled trials, patients (6 to 17 years) with irritability associated with autistic disorder, as well as de novo patients, 60.3% (199/330) completed one year of therapy with Abilify. The mean change in weight z-score was 0.26 SDs for patients receiving >9 months of treatment.

When treating pediatric patients for any indication, weight gain should be monitored and assessed against that expected for normal growth.

Pathological Gambling and Other Compulsive Behaviors

Post-marketing case reports suggest that patients can experience intense urges, particularly for gambling, and the inability to control these urges while taking aripiprazole. Other compulsive urges, reported less frequently, include: sexual urges, shopping, eating or binge eating, and other impulsive or compulsive behaviors. Because patients may not recognize these behaviors as abnormal, it is important for prescribers to ask patients or their caregivers specifically about the development of new or intense gambling urges, compulsive sexual urges, compulsive shopping, binge or compulsive eating, or other urges while being treated with aripiprazole. It should be noted that impulse-control symptoms can be associated with the underlying disorder. In some cases, although not all, urges were reported to have stopped when the dose was reduced or the medication was discontinued. Compulsive behaviors may result in harm to the patient and others if not recognized. Consider dose reduction or stopping the medication if a patient develops such urges.

Orthostatic Hypotension

Abilify may cause orthostatic hypotension, perhaps due to its α 1-adrenergic receptor antagonism. The incidence of orthostatic hypotension-associated events from short-term, placebo-controlled trials of adult patients on oral Abilify (n=2467) included (Abilify incidence, placebo incidence) orthostatic hypotension (1%, 0.3%), postural dizziness (0.5%, 0.3%), and syncope (0.5%, 0.4%); of pediatric patients 6 to 18 years of age (n=732) on oral Abilify included orthostatic hypotension (0.5%, 0%), postural dizziness (0.4%, 0%), and syncope (0.2%, 0%); and of patients on Abilify Injection (n=501) included orthostatic hypotension (0.6%, 0%), postural dizziness (0.2%, 0.5%), and syncope (0.4%, 0%) [see Adverse Reactions (6.1)].

The incidence of a significant orthostatic change in blood pressure (defined as a decrease in systolic blood pressure ≥20 mmHg accompanied by an increase in heart rate ≥25 bpm when comparing standing to supine values) for Abilify was not meaningfully different from placebo (Abilify incidence, placebo incidence): in adult oral Abilify-treated patients (4%, 2%), in pediatric oral Abilify-treated patients aged 6 to 18 years (0.4%, 1%), or in Abilify injection-treated patients (3%, 2%).

Abilify should be used with caution in patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure or conduction abnormalities), cerebrovascular disease, or conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications) [see Drug Interactions (7.1)] .

If parenteral benzodiazepine therapy is deemed necessary in addition to Abilify injection treatment, patients should be monitored for excessive sedation and for orthostatic hypotension [see Drug Interactions (7.1)] .

Falls

Antipsychotics, including Abilify, may cause somnolence, postural hypotension, motor and sensory instability, which may lead to falls and, consequently, fractures or other injuries. For patients with diseases, conditions, or medications that could exacerbate these effects, complete fall risk assessments when initiating antipsychotic treatment and recurrently for patients on long-term antipsychotic therapy.

Leukopenia, Neutropenia, and Agranulocytosis

In clinical trials and/or postmarketing experience, events of leukopenia and neutropenia have been reported temporally related to antipsychotic agents, including Abilify. Agranulocytosis has also been reported.

Possible risk factors for leukopenia/neutropenia include pre-existing low white blood cell count (WBC)/absolute neutrophil count (ANC) and history of drug-induced leukopenia/neutropenia. In patients with a history of a clinically significant low WBC/ANC or drug-induced leukopenia/neutropenia, perform a complete blood count (CBC) frequently during the first few months of therapy. In such patients, consider discontinuation of Abilify at the first sign of a clinically significant decline in WBC in the absence of other causative factors.

Monitor patients with clinically significant neutropenia for fever or other symptoms or signs of infection and treat promptly if such symptoms or signs occur. Discontinue Abilify in patients with severe neutropenia (absolute neutrophil count <1000/mm 3) and follow their WBC counts until recovery.

Seizures/Convulsions

In short-term, placebo-controlled trials, patients with a history of seizures excluded seizures/convulsions occurred in 0.1% (3/2467) of undiagnosed adult patients treated with oral Abilify, in 0.1% (1/732) of pediatric patients (6 to 18 years), and in 0.2% (1/501) of adult Abilify injection-treated patients.

As with other antipsychotic drugs, Abilify should be used cautiously in patients with a history of seizures or with conditions that lower the seizure threshold. Conditions that lower the seizure threshold may be more prevalent in a population of 65 years or older.

Potential for Cognitive and Motor Impairment

Abilify, like other antipsychotics, may have the potential to impair judgment, thinking, or motor skills. For example, in short-term, placebo-controlled trials, somnolence (including sedation) was reported as follows (Abilify incidence, placebo incidence): in adult patients (n=2467) treated with oral Abilify (11%, 6%), in pediatric patients ages 6 to 17 (n=611) (24%, 6%), and in adult patients (n=501) on Abilify Injection (9%, 6%). Somnolence (including sedation) led to discontinuation in 0.3% (8/2467) of adult patients and 3% (20/732) of pediatric patients (6 to 18 years) on oral Abilify in short-term, placebo-controlled trials, but did not lead to discontinuation of any adult patients on Abilify Injection.

Despite the relatively modest increased incidence of these events compared to placebo, patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that therapy with Abilify does not affect them adversely.

Body Temperature Regulation

Disruption of the body’s ability to reduce core body temperature has been attributed to antipsychotic agents. Appropriate care is advised when prescribing Abilify for patients who will be experiencing conditions which may contribute to an elevation in core body temperature, (e.g., exercising strenuously, exposure to extreme heat, receiving concomitant medication with anticholinergic activity, or being subject to dehydration) [see Adverse Reactions (6.2)] .

Suicide

The possibility of a suicide attempt is inherent in psychotic illnesses, bipolar disorder, and major depressive disorder, and close supervision of high-risk patients should accompany drug therapy. Prescriptions for Abilify should be written for the smallest quantity consistent with good patient management in order to reduce the risk of overdose [see Adverse Reactions (6.1, 6.2)] .

Dysphagia

Esophageal dysmotility and aspiration have been associated with antipsychotic drug use, including Abilify. Aspiration pneumonia is a common cause of morbidity and mortality in elderly patients, in particular those with advanced Alzheimer’s dementia. Abilify and other antipsychotic drugs should be used cautiously in patients at risk for aspiration pneumonia [see Warnings and Precautions (5.1) and Adverse Reactions (6.2)].

ردود الفعل السلبية

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The following adverse reactions are discussed in more detail in other sections of the labeling:

  • Increased Mortality in Elderly Patients with Dementia-Related Psychosis [see Boxed Warning and Warnings and Precautions (5.1)]
  • Cerebrovascular Adverse Events, Including Stroke [see Warnings and Precautions (5.2)]
  • Suicidal Thoughts and Behaviors in Children, Adolescents, and Young Adults [see Boxed Warning and Warnings Precautions (5.3)]
  • Neuroleptic Malignant Syndrome (NMS) [see Warnings and Precautions (5.4)]
  • Tardive Dyskinesia [see Warnings and Precautions (5.5)]
  • Metabolic Changes [see Warnings and Precautions (5.6)]
  • Pathological Gambling and Other Compulsive Behaviors [see Warnings and Precautions (5.7)]
  • Orthostatic Hypotension [see Warnings and Precautions (5.8)]
  • Falls [see Warnings and Precautions (5.9)]
  • Leukopenia, Neutropenia, and Agranulocytosis [see Warnings and Precautions (5.10)]
  • Seizures/Convulsions [see Warnings and Precautions (5.11)]
  • Potential for Cognitive and Motor Impairment [see Warnings and Precautions (5.12)]
  • Body Temperature Regulation [see Warnings and Precautions (5.13)]
  • Suicide [see Warnings and Precautions (5.14)]
  • Dysphagia [see Warnings and Precautions (5.15)]

The most common adverse reactions in adult patients in clinical trials (≥10%) were nausea, vomiting, constipation, headache, dizziness, akathisia, anxiety, insomnia, and restlessness.

The most common adverse reactions in the pediatric clinical trials (≥10%) were somnolence, headache, vomiting, extrapyramidal disorder, fatigue, increased appetite, insomnia, nausea, nasopharyngitis, and weight increased.

Abilify has been evaluated for safety in 13,543 adult patients who participated in multiple-dose, clinical trials in schizophrenia, bipolar disorder, major depressive disorder, Dementia of the Alzheimer’s type, Parkinson’s disease, and alcoholism, and who had approximately 7619 patient-years of exposure to oral Abilify and 749 patients with exposure to Abilify injection. A total of 3390 patients were treated with oral Abilify for at least 180 days and 1933 patients treated with oral Abilify had at least 1 year of exposure.

Abilify has been evaluated for safety in 1,686 patients (6 to 18 years) who participated in multiple-dose, clinical trials in schizophrenia, bipolar mania, autistic disorder, or Tourette’s disorder and who had approximately 1,342 patient-years of exposure to oral Abilify. A total of 959 pediatric patients were treated with oral Abilify for at least 180 days and 556 pediatric patients treated with oral Abilify had at least 1 year of exposure.

The conditions and duration of treatment with Abilify (monotherapy and adjunctive therapy with antidepressants or mood stabilizers) included (in overlapping categories) double-blind, comparative and noncomparative open-label studies, inpatient and outpatient studies, fixed- and flexible-dose studies, and short- and longer-term exposure.

Clinical Trials Experience

Adult Patients with Schizophrenia

The following findings are based on a pool of five placebo-controlled trials (four 4-week and one 6-week) in which oral Abilify was administered in doses ranging from 2 to 30 mg/day.

Commonly Observed Adverse Reactions

The only commonly observed adverse reaction associated with the use of Abilify in patients with schizophrenia (incidence of 5% or greater and Abilify incidence at least twice that for placebo) was akathisia (Abilify 8%; placebo 4%).

Adult Patients with Bipolar Mania

Monotherapy

The following findings are based on a pool of 3-week, placebo-controlled, bipolar mania trials in which oral Abilify was administered at doses of 15 or 30 mg/day.

Commonly Observed Adverse Reactions

Commonly observed adverse reactions associated with the use of Abilify in patients with bipolar mania (incidence of 5% or greater and Abilify incidence at least twice that for placebo) are shown in Table 16.

Table 16: Commonly Observed Adverse Reactions in Short-Term, Placebo-Controlled Trials of Adult Patients with Bipolar Mania Treated with Oral Abilify Monotherapy

Percentage of Patients Reporting Reaction
Preferred TermAbilify
(n=917)
Placebo
(n=753)
Akathisia134
Sedation83
Restlessness63
Tremor63
Extrapyramidal Disorder52

Less Common Adverse Reactions in Adults

Table 17 enumerates the pooled incidence, rounded to the nearest percent, of adverse reactions that occurred during acute therapy (up to 6 weeks in schizophrenia and up to 3 weeks in bipolar mania), including only those reactions that occurred in 2% or more of patients treated with Abilify (doses ≥2 mg/day) and for which the incidence in patients treated with Abilify was greater than the incidence in patients treated with placebo in the combined dataset.

Table 17: Adverse Reactions in Short-Term, Placebo-Controlled Trials in Adult Patients Treated with Oral Abilify

Percentage of Patients Reporting Reaction *
System Organ Class
Preferred Term
Abilify
(n=1843)
Placebo
(n=1166)

*
Adverse reactions reported by at least 2% of patients treated with oral Abilify, except adverse reactions which had an incidence equal to or less than placebo.

Eye Disorders
Blurred Vision31
Gastrointestinal Disorders
Nausea1511
Constipation117
Vomiting116
Dyspepsia97
Dry Mouth54
Toothache43
Abdominal Discomfort32
Stomach Discomfort32
General Disorders and Administration Site Conditions
Fatigue64
ألم32
Musculoskeletal and Connective Tissue Disorders
Musculoskeletal Stiffness43
Pain in Extremity42
Myalgia21
Muscle Spasms21
Nervous System Disorders
Headache2723
Dizziness107
Akathisia104
Sedation74
Extrapyramidal Disorder53
Tremor53
Somnolence53
Psychiatric Disorders
Agitation1917
Insomnia1813
Anxiety1713
Restlessness53
Respiratory, Thoracic, and Mediastinal Disorders
Pharyngolaryngeal Pain32
Cough32

An examination of population subgroups did not reveal any clear evidence of differential adverse reaction incidence on the basis of age, gender, or race.

Adult Patients with Adjunctive Therapy with Bipolar Mania

The following findings are based on a placebo-controlled trial of adult patients with bipolar disorder in which Abilify was administered at doses of 15 or 30 mg/day as adjunctive therapy with lithium or valproate.

Adverse Reactions Associated with Discontinuation of Treatment

In a study of patients who were already tolerating either lithium or valproate as monotherapy, discontinuation rates due to adverse reactions were 12% for patients treated with adjunctive Abilify compared to 6% for patients treated with adjunctive placebo. The most common adverse drug reactions associated with discontinuation in the adjunctive Abilify-treated compared to placebo-treated patients were akathisia (5% and 1%, respectively) and tremor (2% and 1%, respectively).

Commonly Observed Adverse Reactions

The commonly observed adverse reactions associated with adjunctive Abilify and lithium or valproate in patients with bipolar mania (incidence of 5% or greater and incidence at least twice that for adjunctive placebo) were: akathisia, insomnia, and extrapyramidal disorder.

Less Common Adverse Reactions in Adult Patients with Adjunctive Therapy in Bipolar Mania

Table 18 enumerates the incidence, rounded to the nearest percent, of adverse reactions that occurred during acute treatment (up to 6 weeks), including only those reactions that occurred in 2% or more of patients treated with adjunctive Abilify (doses of 15 or 30 mg/day) and lithium or valproate and for which the incidence in patients treated with this combination was greater than the incidence in patients treated with placebo plus lithium or valproate.

Table 18: Adverse Reactions in a Short-Term, Placebo-Controlled Trial of Adjunctive Therapy in Patients with Bipolar Disorder

Percentage of Patients Reporting Reaction *
System Organ Class
Preferred Term
Abilify + Li or Val †
(n=253)
Placebo + Li or Val †
(n=130)

*
Adverse reactions reported by at least 2% of patients treated with oral Abilify, except adverse reactions which had an incidence equal to or less than placebo.

Lithium or Valproate

Gastrointestinal Disorders
Nausea85
Vomiting40
Salivary Hypersecretion42
Dry Mouth21
Infections and Infestations
Nasopharyngitis32
Investigations
Weight Increased21
Nervous System Disorders
Akathisia195
Tremor96
Extrapyramidal Disorder51
Dizziness41
Sedation42
Psychiatric Disorders
Insomnia84
Anxiety41
Restlessness21

Pediatric Patients (13 to 17 years) with Schizophrenia

The following findings are based on one 6-week, placebo-controlled trial in which oral Abilify was administered in doses ranging from 2 to 30 mg/day.

Adverse Reactions Associated with Discontinuation of Treatment

The incidence of discontinuation due to adverse reactions between Abilify-treated and placebo-treated pediatric patients (13 to 17 years) was 5% and 2%, respectively.

Commonly Observed Adverse Reactions

Commonly observed adverse reactions associated with the use of Abilify in adolescent patients with schizophrenia (incidence of 5% or greater and Abilify incidence at least twice that for placebo) were extrapyramidal disorder, somnolence, and tremor.

Pediatric Patients (10 to 17 years) with Bipolar Mania

The following findings are based on one 4-week, placebo-controlled trial in which oral Abilify was administered in doses of 10 or 30 mg/day.

Adverse Reactions Associated with Discontinuation of Treatment

The incidence of discontinuation due to adverse reactions between Abilify-treated and placebo-treated pediatric patients (10 to 17 years) was 7% and 2%, respectively.

Commonly Observed Adverse Reactions

Commonly observed adverse reactions associated with the use of Abilify in pediatric patients with bipolar mania (incidence of 5% or greater and Abilify incidence at least twice that for placebo) are shown in Table 19.

Table 19: Commonly Observed Adverse Reactions in Short-Term, Placebo-Controlled Trials of Pediatric Patients (10 to 17 years) with Bipolar Mania Treated with Oral Abilify

Percentage of Patients Reporting Reaction
Preferred TermAbilify
(n=197)
Placebo
(n=97)
Somnolence233
Extrapyramidal Disorder203
Fatigue114
Nausea114
Akathisia102
Blurred Vision80
Salivary Hypersecretion60
Dizziness51

Pediatric Patients (6 to 17 years) with Autistic Disorder

The following findings are based on two 8-week, placebo-controlled trials in which oral Abilify was administered in doses of 2 to 15 mg/day.

Adverse Reactions Associated with Discontinuation of Treatment

The incidence of discontinuation due to adverse reactions between Abilify-treated and placebo-treated pediatric patients (6 to 17 years) was 10% and 8%, respectively.

Commonly Observed Adverse Reactions

Commonly observed adverse reactions associated with the use of Abilify in pediatric patients with autistic disorder (incidence of 5% or greater and Abilify incidence at least twice that for placebo) are shown in Table 20.

Table 20: Commonly Observed Adverse Reactions in Short-Term, Placebo-Controlled Trials of Pediatric Patients (6 to 17 years) with Autistic Disorder Treated with Oral Abilify

Percentage of Patients Reporting Reaction
Preferred TermAbilify
(n=212)
Placebo
(n=101)
Sedation214
Fatigue172
Vomiting147
Somnolence104
Tremor100
Pyrexia91
Drooling90
Decreased Appetite72
Salivary Hypersecretion61
Extrapyramidal Disorder60
Lethargy50

Pediatric Patients (6 to 18 years) with Tourette’s Disorder

The following findings are based on one 8-week and one 10-week, placebo-controlled trials in which oral Abilify was administered in doses of 2 to 20 mg/day.

Adverse Reactions Associated with Discontinuation of Treatment

The incidence of discontinuation due to adverse reactions between Abilify-treated and placebo-treated pediatric patients (6 to 18 years) was 7% and 1%, respectively.

Commonly Observed Adverse Reactions

Commonly observed adverse reactions associated with the use of Abilify in pediatric patients with Tourette’s disorder (incidence of 5% or greater and Abilify incidence at least twice that for placebo) are shown in Table 21.

Table 21: Commonly Observed Adverse Reactions in Short-Term, Placebo-Controlled Trials of Pediatric Patients (6 to 18 years) with Tourette’s Disorder Treated with Oral Abilify

Percentage of Patients Reporting Reaction
Preferred TermAbilify
(n=121)
Placebo
(n=72)
Sedation136
Somnolence131
Nausea114
Headache103
Nasopharyngitis90
Fatigue80
Increased Appetite71

Less Common Adverse Reactions in Pediatric Patients (6 to 18 years) with Schizophrenia, Bipolar Mania, Autistic Disorder, or Tourette’s Disorder

Table 22 enumerates the pooled incidence, rounded to the nearest percent, of adverse reactions that occurred during acute therapy (up to 6 weeks in schizophrenia, up to 4 weeks in bipolar mania, up to 8 weeks in autistic disorder, and up to 10 weeks in Tourette’s disorder), including only those reactions that occurred in 2% or more of pediatric patients treated with Abilify (doses ≥2 mg/day) and for which the incidence in patients treated with Abilify was greater than the incidence in patients treated with placebo.

Table 22: Adverse Reactions in Short-Term, Placebo-Controlled Trials of Pediatric Patients (6 to 18 years) Treated with Oral Abilify

Percentage of Patients Reporting Reaction *
System Organ Class
Preferred Term
Abilify
(n=732)
Placebo
(n=370)

*
Adverse reactions reported by at least 2% of pediatric patients treated with oral Abilify, except adverse reactions which had an incidence equal to or less than placebo.

Eye Disorders
Blurred Vision30
Gastrointestinal Disorders
Abdominal Discomfort21
Vomiting87
Nausea84
Diarrhea43
Salivary Hypersecretion41
Abdominal Pain Upper32
Constipation22
General Disorders and Administration Site Conditions
Fatigue102
Pyrexia41
Irritability21
Asthenia21
Infections and Infestations
Nasopharyngitis63
Investigations
Weight Increased31
Metabolism and Nutrition Disorders
Increased Appetite73
Decreased Appetite54
Musculoskeletal and Connective Tissue Disorders
Musculoskeletal Stiffness21
Muscle Rigidity21
Nervous System Disorders
Somnolence164
Headache1210
Sedation92
Tremor91
Extrapyramidal Disorder61
Akathisia64
Drooling30
Lethargy30
Dizziness32
Dystonia21
Respiratory, Thoracic, and Mediastinal Disorders
Epistaxis21
Skin and Subcutaneous Tissue Disorders
Rash21

Adult Patients Receiving Abilify as Adjunctive Treatment of Major Depressive Disorder

The following findings are based on a pool of two placebo-controlled trials of patients with major depressive disorder in which Abilify was administered at doses of 2 mg to 20 mg as adjunctive treatment to continued antidepressant therapy.

Adverse Reactions Associated with Discontinuation of Treatment

The incidence of discontinuation due to adverse reactions was 6% for adjunctive Abilify-treated patients and 2% for adjunctive placebo-treated patients.

Commonly Observed Adverse Reactions

The commonly observed adverse reactions associated with the use of adjunctive Abilify in patients with major depressive disorder (incidence of 5% or greater and Abilify incidence at least twice that for placebo) were: akathisia, restlessness, insomnia, constipation, fatigue, and blurred vision.

Less Common Adverse Reactions in Adult Patients with Major Depressive Disorder

Table 23 enumerates the pooled incidence, rounded to the nearest percent, of adverse reactions that occurred during acute therapy (up to 6 weeks), including only those adverse reactions that occurred in 2% or more of patients treated with adjunctive Abilify (doses ≥2 mg/day) and for which the incidence in patients treated with adjunctive Abilify was greater than the incidence in patients treated with adjunctive placebo in the combined dataset.

Table 23: Adverse Reactions in Short-Term, Placebo-Controlled Adjunctive Trials in Patients with Major Depressive Disorder

Percentage of Patients Reporting Reaction *
System Organ Class
Preferred Term
Abilify + ADT †
(n=371)
Placebo + ADT †
(n=366)

*
Adverse reactions reported by at least 2% of patients treated with adjunctive Abilify, except adverse reactions which had an incidence equal to or less than placebo.

Antidepressant Therapy

Eye Disorders
Blurred Vision61
Gastrointestinal Disorders
Constipation52
General Disorders and Administration Site Conditions
Fatigue84
Feeling Jittery31
Infections and Infestations
Upper Respiratory Tract Infection64
Investigations
Weight Increased32
Metabolism and Nutrition Disorders
Increased Appetite32
Musculoskeletal and Connective Tissue Disorders
Arthralgia43
Myalgia31
Nervous System Disorders
Akathisia254
Somnolence64
Tremor54
Sedation42
Dizziness42
Disturbance in Attention31
Extrapyramidal Disorder20
Psychiatric Disorders
Restlessness122
Insomnia82

Patients with Agitation Associated with Schizophrenia or Bipolar Mania (Intramuscular Injection)

The following findings are based on a pool of three placebo-controlled trials of patients with agitation associated with schizophrenia or bipolar mania in which Abilify injection was administered at doses of 5.25 mg to 15 mg.

Commonly Observed Adverse Reactions

There was one commonly observed adverse reaction (nausea) associated with the use of Abilify injection in patients with agitation associated with schizophrenia and bipolar mania (incidence of 5% or greater and Abilify incidence at least twice that for placebo).

Less Common Adverse Reactions in Patients with Agitation Associated with Schizophrenia or Bipolar Mania

Table 24 enumerates the pooled incidence, rounded to the nearest percent, of adverse reactions that occurred during acute therapy (24-hour), including only those adverse reactions that occurred in 2% or more of patients treated with Abilify injection (doses ≥5.25 mg/day) and for which the incidence in patients treated with Abilify injection was greater than the incidence in patients treated with placebo in the combined dataset.

Table 24: Adverse Reactions in Short-Term, Placebo-Controlled Trials in Patients Treated with Abilify Injection

Percentage of Patients Reporting Reaction *
System Organ Class
Preferred Term
Abilify
(n=501)
Placebo
(n=220)

*
Adverse reactions reported by at least 2% of patients treated with Abilify injection, except adverse reactions which had an incidence equal to or less than placebo.

Cardiac Disorders
Tachycardia2<1
Gastrointestinal Disorders
Nausea93
Vomiting31
General Disorders and Administration Site Conditions
Fatigue21
Nervous System Disorders
Headache127
Dizziness85
Somnolence74
Sedation32
Akathisia20

Dose-Related Adverse Reactions

Schizophrenia

Dose response relationships for the incidence of treatment-emergent adverse events were evaluated from four trials in adult patients with schizophrenia comparing various fixed doses (2, 5, 10, 15, 20, and 30 mg/day) of oral Abilify to placebo. This analysis, stratified by study, indicated that the only adverse reaction to have a possible dose response relationship, and then most prominent only with 30 mg, was somnolence [including sedation]؛ (incidences were placebo, 7.1%; 10 mg, 8.5%; 15 mg, 8.7%; 20 mg, 7.5%; 30 mg, 12.6%).

In the study of pediatric patients (13 to 17 years of age) with schizophrenia, three common adverse reactions appeared to have a possible dose response relationship: extrapyramidal disorder (incidences were placebo, 5.0%; 10 mg, 13.0%; 30 mg, 21.6%); somnolence (incidences were placebo, 6.0%; 10 mg, 11.0%; 30 mg, 21.6%); and tremor (incidences were placebo, 2.0%; 10 mg, 2.0%; 30 mg, 11.8%).

Bipolar Mania

In the study of pediatric patients (10 to 17 years of age) with bipolar mania, four common adverse reactions had a possible dose response relationship at 4 weeks; extrapyramidal disorder (incidences were placebo, 3.1%; 10 mg, 12.2%; 30 mg, 27.3%); somnolence (incidences were placebo, 3.1%; 10 mg, 19.4%; 30 mg, 26.3%); akathisia (incidences were placebo, 2.1%; 10 mg, 8.2%; 30 mg, 11.1%); and salivary hypersecretion (incidences were placebo, 0%; 10 mg, 3.1%; 30 mg, 8.1%).

Autistic Disorder

In a study of pediatric patients (6 to 17 years of age) with autistic disorder, one common adverse reaction had a possible dose response relationship: fatigue (incidences were placebo, 0%; 5 mg, 3.8%; 10 mg, 22.0%; 15 mg, 18.5%).

Tourette’s Disorder

In a study of pediatric patients (7 to 17 years of age) with Tourette’s disorder, no common adverse reaction(s) had a dose response relationship.

Extrapyramidal Symptoms

Schizophrenia

In short-term, placebo-controlled trials in schizophrenia in adults, the incidence of reported EPS-related events, excluding events related to akathisia, for Abilify-treated patients was 13% vs. 12% for placebo; and the incidence of akathisia-related events for Abilify-treated patients was 8% vs. 4% for placebo. In the short-term, placebo-controlled trial of schizophrenia in pediatric patients (13 to 17 years), the incidence of reported EPS-related events, excluding events related to akathisia, for Abilify-treated patients was 25% vs. 7% for placebo; and the incidence of akathisia-related events for Abilify-treated patients was 9% vs. 6% for placebo.

Objectively collected data from those trials was collected on the Simpson Angus Rating Scale (for EPS), the Barnes Akathisia Scale (for akathisia), and the Assessments of Involuntary Movement Scales (for dyskinesias). In the adult schizophrenia trials, the objectively collected data did not show a difference between Abilify and placebo, with the exception of the Barnes Akathisia Scale (Abilify, 0.08; placebo, –0.05). In the pediatric (13 to 17 years) schizophrenia trial, the objectively collected data did not show a difference between Abilify and placebo, with the exception of the Simpson Angus Rating Scale (Abilify, 0.24; placebo, –0.29).

Similarly, in a long-term (26-week), placebo-controlled trial of schizophrenia in adults, objectively collected data on the Simpson Angus Rating Scale (for EPS), the Barnes Akathisia Scale (for akathisia), and the Assessments of Involuntary Movement Scales (for dyskinesias) did not show a difference between Abilify and placebo.

Bipolar Mania

In the short-term, placebo-controlled trials in bipolar mania in adults, the incidence of reported EPS-related events, excluding events related to akathisia, for monotherapy Abilify-treated patients was 16% vs. 8% for placebo and the incidence of akathisia-related events for monotherapy Abilify-treated patients was 13% vs. 4% for placebo. In the 6-week, placebo-controlled trial in bipolar mania for adjunctive therapy with lithium or valproate, the incidence of reported EPS-related events, excluding events related to akathisia for adjunctive Abilify-treated patients was 15% vs. 8% for adjunctive placebo and the incidence of akathisia-related events for adjunctive Abilify-treated patients was 19% vs. 5% for adjunctive placebo. In the short-term, placebo-controlled trial in bipolar mania in pediatric (10 to 17 years) patients, the incidence of reported EPS-related events, excluding events related to akathisia, for Abilify-treated patients was 26% vs. 5% for placebo and the incidence of akathisia-related events for Abilify-treated patients was 10% vs. 2% for placebo.

In the adult bipolar mania trials with monotherapy Abilify, the Simpson Angus Rating Scale and the Barnes Akathisia Scale showed a significant difference between Abilify and placebo (Abilify, 0.50; placebo, –0.01 and Abilify, 0.21; placebo, –0.05). Changes in the Assessments of Involuntary Movement Scales were similar for the Abilify and placebo groups. In the bipolar mania trials with Abilify as adjunctive therapy with either lithium or valproate, the Simpson Angus Rating Scale and the Barnes Akathisia Scale showed a significant difference between adjunctive Abilify and adjunctive placebo (Abilify, 0.73; placebo, 0.07 and Abilify, 0.30; placebo, 0.11). Changes in the Assessments of Involuntary Movement Scales were similar for adjunctive Abilify and adjunctive placebo. In the pediatric (10 to 17 years), short-term, bipolar mania trial, the Simpson Angus Rating Scale showed a significant difference between Abilify and placebo (Abilify, 0.90; placebo, −0.05). Changes in the Barnes Akathisia Scale and the Assessments of Involuntary Movement Scales were similar for the Abilify and placebo groups.

Major Depressive Disorder

In the short-term, placebo-controlled trials in major depressive disorder, the incidence of reported EPS-related events, excluding events related to akathisia, for adjunctive Abilify-treated patients was 8% vs. 5% for adjunctive placebo-treated patients; and the incidence of akathisia-related events for adjunctive Abilify-treated patients was 25% vs. 4% for adjunctive placebo-treated patients.

In the major depressive disorder trials, the Simpson Angus Rating Scale and the Barnes Akathisia Scale showed a significant difference between adjunctive Abilify and adjunctive placebo (Abilify, 0.31; placebo, 0.03 and Abilify, 0.22; placebo, 0.02). Changes in the Assessments of Involuntary Movement Scales were similar for the adjunctive Abilify and adjunctive placebo groups.

Autistic Disorder

In the short-term, placebo-controlled trials in autistic disorder in pediatric patients (6 to 17 years), the incidence of reported EPS-related events, excluding events related to akathisia, for Abilify-treated patients was 18% vs. 2% for placebo and the incidence of akathisia-related events for Abilify-treated patients was 3% vs. 9% for placebo.

In the pediatric (6 to 17 years) short-term autistic disorder trials, the Simpson Angus Rating Scale showed a significant difference between Abilify and placebo (Abilify, 0.1; placebo, –0.4). Changes in the Barnes Akathisia Scale and the Assessments of Involuntary Movement Scales were similar for the Abilify and placebo groups.

Tourette’s Disorder

In the short-term, placebo-controlled trials in Tourette’s disorder in pediatric patients (6 to 18 years), the incidence of reported EPS-related events, excluding events related to akathisia, for Abilify-treated patients was 7% vs. 6% for placebo and the incidence of akathisia-related events for Abilify-treated patients was 4% vs. 6% for placebo.

In the pediatric (6 to 18 years) short-term Tourette’s disorder trials, changes in the Simpson Angus Rating Scale, Barnes Akathisia Scale and Assessments of Involuntary Movement Scale were not clinically meaningfully different for Abilify and placebo.

Agitation Associated with Schizophrenia or Bipolar Mania

In the placebo-controlled trials in patients with agitation associated with schizophrenia or bipolar mania, the incidence of reported EPS-related events excluding events related to akathisia for Abilify-treated patients was 2% vs. 2% for placebo and the incidence of akathisia-related events for Abilify-treated patients was 2% vs. 0% for placebo. Objectively collected data on the Simpson Angus Rating Scale (for EPS) and the Barnes Akathisia Scale (for akathisia) for all treatment groups did not show a difference between Abilify and placebo.

Dystonia

Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment. Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue. While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first generation antipsychotic drugs. An elevated risk of acute dystonia is observed in males and younger age groups.

Additional Findings Observed in Clinical Trials

Adverse Reactions in Long-Term, Double-Blind, Placebo-Controlled Trials

The adverse reactions reported in a 26-week, double-blind trial comparing oral Abilify and placebo in patients with schizophrenia were generally consistent with those reported in the short-term, placebo-controlled trials, except for a higher incidence of tremor [8% (12/153) for Abilify vs. 2% (3/153) for placebo]. In this study, the majority of the cases of tremor were of mild intensity (8/12 mild and 4/12 moderate), occurred early in therapy (9/12 ≤49 days), and were of limited duration (7/12 ≤10 days). Tremor infrequently led to discontinuation (<1%) of Abilify. In addition, in a long-term (52 weeks), active-controlled study, the incidence of tremor was 5% (40/859) for Abilify. A similar profile was observed in a long-term monotherapy study and a long-term adjunctive study with lithium and valproate in bipolar disorder.

Other Adverse Reactions Observed During the Premarketing Evaluation of Abilify

The following listing does not include reactions: 1) already listed in previous tables or elsewhere in labeling, 2) for which a drug cause was remote, 3) which were so general as to be uninformative, 4) which were not considered to have significant clinical implications, or 5) which occurred at a rate equal to or less than placebo.

Reactions are categorized by body system according to the following definitions: frequent adverse reactions are those occurring in at least 1/100 patients; infrequent adverse reactions are those occurring in 1/100 to 1/1000 patients; rare reactions are those occurring in fewer than 1/1000 patients:

Adults – Oral Administration

Blood and Lymphatic System Disorders:

rare – thrombocytopenia

Cardiac Disorders:

infrequent – bradycardia, palpitations, rare – atrial flutter, cardio-respiratory arrest, atrioventricular block, atrial fibrillation, angina pectoris, myocardial ischemia, myocardial infarction, cardiopulmonary failure

Eye Disorders:

infrequent – photophobia; rare – diplopia

Gastrointestinal Disorders:

infrequent – gastroesophageal reflux disease

General Disorders and Administration Site Conditions:

frequent – asthenia; infrequent – peripheral edema, chest pain; rare – face edema

Hepatobiliary Disorders:

rare – hepatitis, jaundice

Immune System Disorders:

rare – hypersensitivity

Injury, Poisoning, and Procedural Complications:

infrequent – fall; rare – heat stroke

Investigations:

frequent – weight decreased, infrequent – hepatic enzyme increased, blood glucose increased, blood lactate dehydrogenase increased, gamma glutamyl transferase increased; rare – blood prolactin increased, blood urea increased, blood creatinine increased, blood bilirubin increased, electrocardiogram QT prolonged, glycosylated hemoglobin increased

Metabolism and Nutrition Disorders:

frequent – anorexia; rare – hypokalemia, hyponatremia, hypoglycemia

Musculoskeletal and Connective Tissue Disorders:

infrequent – muscular weakness, muscle tightness; rare – rhabdomyolysis, mobility decreased

Nervous System Disorders:

infrequent – parkinsonism, memory impairment, cogwheel rigidity, hypokinesia, bradykinesia; rare – akinesia, myoclonus, coordination abnormal, speech disorder, Grand Mal convulsion; <1/10,000 patients - choreoathetosis

Psychiatric Disorders:

infrequent – aggression, loss of libido, delirium; rare – libido increased, anorgasmia, tic, homicidal ideation, catatonia, sleep walking

Renal and Urinary Disorders:

rare – urinary retention, nocturia

Reproductive System and Breast Disorders:

infrequent – erectile dysfunction; rare – gynaecomastia, menstruation irregular, amenorrhea, breast pain, priapism

Respiratory, Thoracic, and Mediastinal Disorders:

infrequent – nasal congestion, dyspnea

Skin and Subcutaneous Tissue Disorders:

infrequent – rash, hyperhidrosis, pruritus, photosensitivity reaction, alopecia; rare – urticaria

Vascular Disorders:

infrequent – hypotension, hypertension

Pediatric Patients – Oral Administration

Most adverse events observed in the pooled database of 1,686 pediatric patients, aged 6 to 18 years, were also observed in the adult population. Additional adverse reactions observed in the pediatric population are listed below.

Eye Disorders

infrequent – oculogyric crisis

Gastrointestinal Disorders:

infrequent -tongue dry, tongue spasm

Investigations:

frequent – blood insulin increased

Nervous System Disorders:

infrequent – sleep talking

Renal and Urinary Disorders

frequent – enuresis

Skin and Subcutaneous Tissue Disorders:

infrequent – hirsutism

Adults – Intramuscular Injection

Most adverse reactions observed in the pooled database of 749 adult patients treated with Abilify injection, were also observed in the adult population treated with oral Abilify. Additional adverse reactions observed in the Abilify injection population are listed below.

General Disorders and Administration Site Conditions:

≥1/100 patients – injection site reaction; ≥1/1000 patients and <1/100 patients - venipuncture site bruise

Postmarketing Experience

The following adverse reactions have been identified during post-approval use of Abilify. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to establish a causal relationship to drug exposure: occurrences of allergic reaction (anaphylactic reaction, angioedema, laryngospasm, pruritus/urticaria, or oropharyngeal spasm), pathological gambling, hiccups, blood glucose fluctuation, oculogyric crisis and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS).

Drug Interactions

Drugs Having Clinically Important Interactions with Abilify

Table 25: Clinically Important Drug Interactions with Abilify:

Concomitant Drug Name or Drug ClassClinical RationaleClinical Recommendation
Strong CYP3A4 Inhibitors (e.g., itraconazole, clarithromycin) or strong CYP2D6 inhibitors (e.g., quinidine, fluoxetine, paroxetine)The concomitant use of Abilify with strong CYP 3A4 or CYP2D6 inhibitors increased the exposure of aripiprazole compared to the use of Abilify alone [see Clinical Pharmacology (12.3)].With concomitant use of Abilify with a strong CYP3A4 inhibitor or CYP2D6 inhibitor, reduce the Abilify dosage [see Dosage and Administration (2.7)] .
Strong CYP3A4 Inducers (e.g., carbamazepine, rifampin)The concomitant use of Abilify and carbamazepine decreased the exposure of aripiprazole compared to the use of Abilify alone [see Clinical Pharmacology (12.3)] .With concomitant use of Abilify with a strong CYP3A4 inducer, consider increasing the Abilify dosage [see Dosage and Administration (2.7)] .
Antihypertensive DrugsDue to its alpha adrenergic antagonism, aripiprazole has the potential to enhance the effect of certain antihypertensive agents.Monitor blood pressure and adjust dose accordingly [see Warnings and Precautions (5.8)] .
Benzodiazepines (e.g., lorazepam)The intensity of sedation was greater with the combination of oral aripiprazole and lorazepam as compared to that observed with aripiprazole alone. The orthostatic hypotension observed was greater with the combination as compared to that observed with lorazepam alone [see Warnings and Precautions (5.8)].Monitor sedation and blood pressure. Adjust dose accordingly.

Drugs Having No Clinically Important Interactions with Abilify

Based on pharmacokinetic studies, no dosage adjustment of Abilify is required when administered concomitantly with famotidine, valproate, lithium, lorazepam.

In addition, no dosage adjustment is necessary for substrates of CYP2D6 (e.g., dextromethorphan, fluoxetine, paroxetine, or venlafaxine), CYP2C9 (e.g., warfarin), CYP2C19 (e.g., omeprazole, warfarin, escitalopram), or CYP3A4 (e.g., dextromethorphan) when co-administered with Abilify. Additionally, no dosage adjustment is necessary for valproate, lithium, lamotrigine, lorazepam, or sertraline when co-administered with Abilify [see Clinical Pharmacology (12.3)] .

الاستخدام في مجموعات محددة

حمل

Pregnancy Exposure Registry

There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to atypical antipsychotics, including Abilify, during pregnancy. Healthcare providers are encouraged to register patients by contacting the National Pregnancy Registry for Atypical Antipsychotics at 1-866-961-2388 or visit http://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/.

ملخص المخاطر

Neonates exposed to antipsychotic drugs, including Abilify, during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery (see Clinical Considerations) . Overall available data from published epidemiologic studies of pregnant women exposed to aripiprazole have not established a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes (see Data) . There are risks to the mother associated with untreated schizophrenia, bipolar I disorder, or major depressive disorder, and with exposure to antipsychotics, including Abilify, during pregnancy (see Clinical Considerations).

In animal reproduction studies, oral and intravenous aripiprazole administration during organogenesis in rats and/or rabbits at doses 10 and 19 times, respectively, the maximum recommended human dose (MRHD) of 30 mg/day based on mg/m 2 body surface area, produced fetal death, decreased fetal weight, undescended testicles, delayed skeletal ossification, skeletal abnormalities, and diaphragmatic hernia. Oral and intravenous aripiprazole administration during the pre- and post-natal period in rats at doses 10 times the MRHD based on mg/m 2 body surface area, produced prolonged gestation, stillbirths, decreased pup weight, and decreased pup survival (see Data) .

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

اعتبارات سريرية

Disease-associated maternal and/or embryo/fetal risk

There is a risk to the mother from untreated schizophrenia or bipolar I disorder, including increased risk of relapse, hospitalization, and suicide. Schizophrenia and bipolar I disorder are associated with increased adverse perinatal outcomes, including preterm birth. It is not known if this is a direct result of the illness or other comorbid factors.

A prospective, longitudinal study followed 201 pregnant women with a history of major depressive disorder who were euthymic and taking antidepressants at the beginning of pregnancy. The women who discontinued antidepressants during pregnancy were more likely to experience a relapse of major depression than women who continued antidepressants. Consider the risk of untreated depression when discontinuing or changing treatment with antidepressant medication during pregnancy and postpartum.

Fetal/Neonatal Adverse Reactions

Extrapyramidal and/or withdrawal symptoms, including agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, and feeding disorder have been reported in neonates who were exposed to antipsychotic drugs (including Abilify) during the third trimester of pregnancy. These symptoms have varied in severity. Monitor neonates for extrapyramidal and/or withdrawal symptoms, and manage symptoms appropriately. Some neonates recovered within hours or days without specific treatment; others required prolonged hospitalization.

البيانات

Human Data

Published data from observational studies, birth registries, and case reports on the use of atypical antipsychotics during pregnancy do not report a clear association with antipsychotics and major birth defects. A retrospective study from a Medicaid database of 9258 women exposed to antipsychotics during pregnancy did not indicate an overall increased risk for major birth defects.

Animal Data

In animal studies, aripiprazole demonstrated developmental toxicity, including possible teratogenic effects in rats and rabbits.

In pregnant rats treated orally with aripiprazole during organogenesis at doses of 3, 10, and 30 mg/kg/day, which are approximately 1, 3 and 10 times the MRHD of 30 mg/day based on mg/m 2 body surface area, a slight prolongation of gestation and delay in fetal development, as evidenced by decreased fetal weight and undescended testes, were observed at 10 times the MRHD. Delayed skeletal ossification was observed at 3 and 10 times the MRHD. Delivered offspring had increased incidences of hepatodiaphragmatic nodules and diaphragmatic hernia were observed at 10 times the MRHD (the other dose groups were not examined for these findings). Postnatally, delayed vaginal opening was seen at 3 and 10 times the MRHD. Impaired reproductive performance (decreased fertility rate, corpora lutea, implants, live fetuses, and increased post-implantation loss, likely mediated through effects on female offspring) were observed at 10 times the MRHD; however, there was no evidence to suggest that these developmental effects were secondary to maternal toxicity.

In pregnant rats injected intravenously with aripiprazole during organogenesis at doses of 3, 9, and 27 mg/kg/day, which are 1, 3, and 9 times the MRHD of 30 mg/day based on mg/m 2 body surface area, decreased fetal weight and delayed skeletal ossification were observed at 9 times the MRHD; this dose also caused maternal toxicity.

In pregnant rabbits treated orally with aripiprazole during organogenesis at doses of 10, 30, and 100 mg/kg/day which are 6, 19, and 65 times the MRHD of 30 mg/day based on mg/m 2 body surface area, decreased maternal food consumption, and increased abortions as well as increased fetal mortality were observed at 65 times the MHRD. Decreased fetal weight and increased incidence of fused sternebrae were observed at 19 and 65 times the MRHD.

In pregnant rabbits injected intravenously with aripiprazole during organogenesis at doses of 3, 10, and 30 mg/kg/day, which are 2, 6, and 19 times the MRHD of 30 mg/day based on mg/m 2 body surface area, decreased fetal weight, increased fetal abnormalities (primarily skeletal), and decreased fetal skeletal ossification were observed at 19 times the MRHD; this dose also caused maternal toxicity. The fetal no-effect dose was 10 mg/kg/day, which is 6 times the MRHD.

In rats treated orally with aripiprazole peri- and post-natally from gestation day 17 through postpartum day 21 at doses of 3, 10, and 30 mg/kg/day which are 1, 3, and 10 times the MRHD of 30 mg/day based on mg/m 2 body surface area slight maternal toxicity and slightly prolonged gestation were observed at 10 times the MHRD. An increase in stillbirths and, decreases in pup weight (persisting into adulthood) and survival were also seen at this dose.

In rats injected intravenously with aripiprazole from gestation day 6 through lactation day 20 at doses of 3, 8, and 20 mg/kg/day, which are 1, 3, and 6 times the MRHD of 30 mg/day based on mg/m 2 body surface area, increased stillbirths were observed at 3 and 6 times the MRHD; and decreases in early postnatal pup weight and survival were observed at 6 times the MRHD; these doses also caused some maternal toxicity. There were no effects on postnatal behavioral and reproductive development.

الرضاعة

ملخص المخاطر

Limited data from published literature report the presence of aripiprazole in human breast milk, at relative infant doses ranging between 0.7% to 8.3% of the maternal weight-adjusted dosage. There are reports of poor weight gain in breastfed infants exposed to aripiprazole and reports of inadequate milk supply in lactating women taking aripiprazole.

The development and health benefits of breastfeeding should be considered along with the mother’s clinical need for Abilify and any potential adverse effects on the breastfed infant from Abilify or from the underlying maternal condition.

استخدام الأطفال

Safety and effectiveness in pediatric patients with major depressive disorder or agitation associated with schizophrenia or bipolar mania have not been established.

The pharmacokinetics of aripiprazole and dehydro-aripiprazole in pediatric patients, 10 to 17 years of age, were similar to those in adults after correcting for the differences in body weight [see Clinical Pharmacology (12.3)] .

Schizophrenia

Safety and effectiveness in pediatric patients with schizophrenia were established in a 6-week, placebo-controlled clinical trial in 202 pediatric patients aged 13 to 17 years [see Dosage and Administration (2.1), Adverse Reactions (6.1), and Clinical Studies (14.1)] . Although maintenance efficacy in pediatric patients has not been systematically evaluated, maintenance efficacy can be extrapolated from adult data along with comparisons of aripiprazole pharmacokinetic parameters in adult and pediatric patients.

Bipolar I Disorder

Safety and effectiveness in pediatric patients with bipolar mania were established in a 4-week, placebo-controlled clinical trial in 197 pediatric patients aged 10 to 17 years [see Dosage and Administration (2.2), Adverse Reactions (6.1), and Clinical Studies (14.2)] . Although maintenance efficacy in pediatric patients has not been systematically evaluated, maintenance efficacy can be extrapolated from adult data along with comparisons of aripiprazole pharmacokinetic parameters in adult and pediatric patients.

The efficacy of adjunctive Abilify with concomitant lithium or valproate in the treatment of manic or mixed episodes in pediatric patients has not been systematically evaluated. However, such efficacy and lack of pharmacokinetic interaction between aripiprazole and lithium or valproate can be extrapolated from adult data, along with comparisons of aripiprazole pharmacokinetic parameters in adult and pediatric patients.

Irritability Associated with Autistic Disorder

Safety and effectiveness in pediatric patients demonstrating irritability associated with autistic disorder were established in two 8-week, placebo-controlled clinical trials in 212 pediatric patients aged 6 to 17 years [see Indications and Usage (1), Dosage and Administration (2.4), Adverse Reactions (6.1), and Clinical Studies (14.4)] . A maintenance trial was conducted in pediatric patients (6 to 17 years of age) with irritability associated with autistic disorder. The first phase of this trial was an open-label, flexibly dosed (aripiprazole 2 to 15 mg/day) phase in which patients were stabilized (defined as >25% improvement on the ABC-I subscale, and a CGI-I rating of “much improved” or “very much improved”) on Abilify for 12 consecutive weeks. Overall, 85 patients were stabilized and entered the second, 16-week, double-blind phase where they were randomized to either continue Abilify treatment or switch to placebo. In this trial, the efficacy of Abilify for the maintenance treatment of irritability associated with autistic disorder was not established.

Tourette’s Disorder

Safety and effectiveness of aripiprazole in pediatric patients with Tourette’s Disorder were established in one 8-week (aged 7 to 17) and one 10-week trial (aged 6 to 18) in 194 pediatric patients [see Dosage and Administration (2.5), Adverse Reactions (6.1), and Clinical Studies (14.5)] . Maintenance efficacy in pediatric patients has not been systematically evaluated.

Juvenile Animal Studies

Aripiprazole in juvenile rats caused mortality, CNS clinical signs, impaired memory and learning, and delayed sexual maturation when administered at oral doses of 10, 20, 40 mg/kg/day from weaning (21 days old) through maturity (80 days old). At 40 mg/kg/day, mortality, decreased activity, splayed hind limbs, hunched posture, ataxia, tremors and other CNS signs were observed in both genders. In addition, delayed sexual maturation was observed in males. At all doses and in a dose-dependent manner, impaired memory and learning, increased motor activity, and histopathology changes in the pituitary (atrophy), adrenals (adrenocortical hypertrophy), mammary glands (hyperplasia and increased secretion), and female reproductive organs (vaginal mucification, endometrial atrophy, decrease in ovarian corpora lutea) were observed. The changes in female reproductive organs were considered secondary to the increase in prolactin serum levels. A No Observed Adverse Effect Level (NOAEL) could not be determined and, at the lowest tested dose of 10 mg/kg/day, there is no safety margin relative to the systemic exposures (AUC 0-24) for aripiprazole or its major active metabolite in adolescents at the maximum recommended pediatric dose of 15 mg/day. All drug-related effects were reversible after a 2-month recovery period, and most of the drug effects in juvenile rats were also observed in adult rats from previously conducted studies.

Aripiprazole in juvenile dogs (2 months old) caused CNS clinical signs of tremors, hypoactivity, ataxia, recumbency and limited use of hind limbs when administered orally for 6 months at 3, 10, 30 mg/kg/day. Mean body weight and weight gain were decreased up to 18% in females in all drug groups relative to control values. A NOAEL could not be determined and, at the lowest tested dose of 3 mg/kg/day, there is no safety margin relative to the systemic exposures (AUC 0-24) for aripiprazole or its major active metabolite in adolescents at the maximum recommended pediatric dose of 15 mg/day. All drug-related effects were reversible after a 2-month recovery period.

استخدام الشيخوخة

No dosage adjustment is recommended for elderly patients [see Boxed Warning, Warnings and Precautions (5.1), and Clinical Pharmacology (12.3)] .

Of the 13,543 patients treated with oral Abilify in clinical trials, 1073 (8%) were ≥65 years old and 799 (6%) were ≥75 years old. Placebo-controlled studies of oral Abilify in schizophrenia, bipolar mania, or major depressive disorder did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.

Of the 749 patients treated with Abilify injection in clinical trials, 99 (13%) were ≥65 years old and 78 (10%) were ≥75 years old. Placebo-controlled studies of Abilify injection in patients with agitation associated with schizophrenia or bipolar mania did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.

Abilify is not approved for the treatment of patients with psychosis associated with Alzheimer’s disease [see Boxed Warning and Warnings and Precautions (5.1)] .

CYP2D6 Poor Metabolizers

Dosage adjustment is recommended in known CYP2D6 poor metabolizers due to high aripiprazole concentrations. Approximately 8% of Caucasians and 3 to 8% of Black/African Americans cannot metabolize CYP2D6 substrates and are classified as poor metabolizers (PM) [see Dosage and Administration (2.7) and Clinical Pharmacology (12.3)].

Hepatic and Renal Impairment

No dosage adjustment for Abilify is required on the basis of a patient’s hepatic function (mild to severe hepatic impairment, Child-Pugh score between 5 and 15), or renal function (mild to severe renal impairment, glomerular filtration rate between 15 and 90 mL/minute) [see Clinical Pharmacology (12.3)] .

Other Specific Populations

No dosage adjustment for Abilify is required on the basis of a patient’s sex, race, or smoking status [see Clinical Pharmacology (12.3)] .

Drug Abuse and Dependence

Controlled Substance

Abilify is not a controlled substance.

Abuse

Abilify has not been systematically studied in humans for its potential for abuse, tolerance, or physical dependence. Consequently, patients should be evaluated carefully for a history of drug abuse, and such patients should be observed closely for signs of Abilify misuse or abuse (e.g., development of tolerance, increases in dose, drug-seeking behavior).

Dependence

In physical dependence studies in monkeys, withdrawal symptoms were observed upon abrupt cessation of dosing. While the clinical trials did not reveal any tendency for any drug-seeking behavior, these observations were not systematic and it is not possible to predict on the basis of this limited experience the extent to which a CNS-active drug will be misused, diverted, and/or abused once marketed.

جرعة مفرطة

MedDRA terminology has been used to classify the adverse reactions.

Human Experience

In clinical trials and in postmarketing experience, adverse reactions of deliberate or accidental overdosage with oral Abilify have been reported worldwide. These include overdoses with oral Abilify alone and in combination with other substances. No fatality was reported with Abilify alone. The largest known dose with a known outcome involved acute ingestion of 1260 mg of oral Abilify (42 times the maximum recommended daily dose) by a patient who fully recovered. Deliberate or accidental overdosage was also reported in children (age 12 and younger) involving oral Abilify ingestions up to 195 mg with no fatalities.

Common adverse reactions (reported in at least 5% of all overdose cases) reported with oral Abilify overdosage (alone or in combination with other substances) include vomiting, somnolence, and tremor. Other clinically important signs and symptoms observed in one or more patients with Abilify overdoses (alone or with other substances) include acidosis, aggression, aspartate aminotransferase increased, atrial fibrillation, bradycardia, coma, confusional state, convulsion, blood creatine phosphokinase increased, depressed level of consciousness, hypertension, hypokalemia, hypotension, lethargy, loss of consciousness, QRS complex prolonged, QT prolonged, pneumonia aspiration, respiratory arrest, status epilepticus, and tachycardia.

Management of Overdosage

No specific information is available on the treatment of overdose with Abilify. An electrocardiogram should be obtained in case of overdosage and if QT interval prolongation is present, cardiac monitoring should be instituted. Otherwise, management of overdose should concentrate on supportive therapy, maintaining an adequate airway, oxygenation and ventilation, and management of symptoms. Close medical supervision and monitoring should continue until the patient recovers.

Charcoal: In the event of an overdose of Abilify, an early charcoal administration may be useful in partially preventing the absorption of aripiprazole. Administration of 50 g of activated charcoal, one hour after a single 15 mg oral dose of Abilify, decreased the mean AUC and C max of aripiprazole by 50%.

Hemodialysis: Although there is no information on the effect of hemodialysis in treating an overdose with Abilify, hemodialysis is unlikely to be useful in overdose management since aripiprazole is highly bound to plasma proteins.

Abilify Description

Aripiprazole is an atypical antipsychotic drug that is available as Abilify ® (aripiprazole) Tablets, Abilify DISCMELT ® (aripiprazole) Orally Disintegrating Tablets, Abilify ® (aripiprazole) Oral Solution, and Abilify ® (aripiprazole) Injection, a solution for intramuscular injection. Aripiprazole is 7-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydrocarbostyril. The empirical formula is C 23H 27C l2N 3O 2 and its molecular weight is 448.38. The chemical structure is:

Abilify Tablets are available in 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg strengths. Inactive ingredients include cornstarch, hydroxypropyl cellulose, lactose monohydrate, magnesium stearate, and microcrystalline cellulose. Colorants include ferric oxide (yellow or red) and FD&C Blue No. 2 Aluminum Lake.

Abilify DISCMELT Orally Disintegrating Tablets are available in 10 mg and 15 mg strengths. Inactive ingredients include acesulfame potassium, aspartame, calcium silicate, croscarmellose sodium, crospovidone, crème de vanilla (natural and artificial flavors), magnesium stearate, microcrystalline cellulose, silicon dioxide, tartaric acid, and xylitol. Colorants include ferric oxide (yellow or red) and FD&C Blue No. 2 Aluminum Lake.

Abilify Oral Solution is a clear, colorless to light-yellow solution available in a concentration of 1 mg/mL. The inactive ingredients for this solution include disodium edetate, fructose, glycerin, dl-lactic acid, methylparaben, propylene glycol, propylparaben, sodium hydroxide, sucrose, and purified water. The oral solution is flavored with natural orange cream and other natural flavors.

Abilify Injection is available in single-dose vials as a ready-to-use, 9.75 mg/1.3 mL (7.5 mg/mL) clear, colorless, sterile, aqueous solution for intramuscular use only. Inactive ingredients for this solution include 199.5 mg of sulfobutylether β-cyclodextrin (SBECD), 10.4 mg of tartaric acid, qs to pH 4.3 of sodium hydroxide, and qs to 1.33 mL of water for injection.

Abilify – Clinical Pharmacology

آلية العمل

The mechanism of action of aripiprazole in schizophrenia or bipolar mania, is unclear. However, the efficacy of aripiprazole in the listed indications could be mediated through a combination of partial agonist activity at D 2 and 5-HT 1A receptors and antagonist activity at 5-HT 2A receptors.

الديناميكا الدوائية

Aripiprazole exhibits high affinity for dopamine D 2 and D 3, serotonin 5-HT 1A and 5-HT 2A receptors (K i values of 0.34 nM, 0.8 nM, 1.7 nM, and 3.4 nM, respectively), moderate affinity for dopamine D 4, serotonin 5-HT 2C and 5-HT 7, alpha 1-adrenergic and histamine H 1 receptors (K i values of 44 nM, 15 nM, 39 nM, 57 nM, and 61 nM, respectively), and moderate affinity for the serotonin reuptake site (K i=98 nM). Aripiprazole has no appreciable affinity for cholinergic muscarinic receptors (IC 50>1000 nM).

الدوائية

Abilify activity is presumably primarily due to the parent drug, aripiprazole, and to a lesser extent, to its major metabolite, dehydro-aripiprazole, which has been shown to have affinities for D 2 receptors similar to the parent drug and represents 40% of the parent drug exposure in plasma. The mean elimination half-lives are about 75 hours and 94 hours for aripiprazole and dehydro-aripiprazole, respectively. Steady-state concentrations are attained within 14 days of dosing for both active moieties. Aripiprazole accumulation is predictable from single-dose pharmacokinetics. At steady-state, the pharmacokinetics of aripiprazole is dose-proportional. Elimination of aripiprazole is mainly through hepatic metabolism involving two P450 isozymes, CYP2D6 and CYP3A4. For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.

Pharmacokinetic studies showed that Abilify DISCMELT Orally Disintegrating Tablets are bioequivalent to Abilify Tablets.

ORAL ADMINISTRATION

استيعاب

Tablet: Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%. Abilify can be administered with or without food. Administration of a 15 mg Abilify Tablet with a standard high-fat meal did not significantly affect the C max or AUC of aripiprazole or its active metabolite, dehydro-aripiprazole, but delayed T max by 3 hours for aripiprazole and 12 hours for dehydro-aripiprazole.

Oral Solution: Aripiprazole is well absorbed when administered orally as the solution. At equivalent doses, the plasma concentrations of aripiprazole from the solution were higher than that from the tablet formulation. In a relative bioavailability study comparing the pharmacokinetics of 30 mg aripiprazole as the oral solution to 30 mg aripiprazole tablets in healthy subjects, the solution to tablet ratios of geometric mean C max and AUC values were 122% and 114%, respectively [see Dosage and Administration (2.6)] . The single-dose pharmacokinetics of aripiprazole were linear and dose-proportional between the doses of 5 mg to 30 mg.

توزيع

The steady-state volume of distribution of aripiprazole following intravenous administration is high (404 L or 4.9 L/kg), indicating extensive extravascular distribution. At therapeutic concentrations, aripiprazole and its major metabolite are greater than 99% bound to serum proteins, primarily to albumin. In healthy human volunteers administered 0.5 to 30 mg/day aripiprazole for 14 days, there was dose-dependent D2 receptor occupancy indicating brain penetration of aripiprazole in humans.

Metabolism and Elimination

Aripiprazole is metabolized primarily by three biotransformation pathways: dehydrogenation, hydroxylation, and N-dealkylation. Based on in vitro studies, CYP3A4 and CYP2D6 enzymes are responsible for dehydrogenation and hydroxylation of aripiprazole, and N-dealkylation is catalyzed by CYP3A4. Aripiprazole is the predominant drug moiety in the systemic circulation. At steady-state, dehydro-aripiprazole, the active metabolite, represents about 40% of aripiprazole AUC in plasma.

Following a single oral dose of [ 14C]-labeled aripiprazole, approximately 25% and 55% of the administered radioactivity was recovered in the urine and feces, respectively. Less than 1% of unchanged aripiprazole was excreted in the urine and approximately 18% of the oral dose was recovered unchanged in the feces.

Drug Interaction Studies

Effects of other drugs on the exposures of aripiprazole and dehydro-aripiprazole are summarized in Figure 1 and Figure 2, respectively. Based on simulation, a 4.5-fold increase in mean C max and AUC values at steady-state is expected when extensive metabolizers of CYP2D6 are administered with both strong CYP2D6 and CYP3A4 inhibitors. A 3-fold increase in mean C max and AUC values at steady-state is expected in poor metabolizers of CYP2D6 administered with strong CYP3A4 inhibitors.

Figure 1: The Effects of Other Drugs on Aripiprazole Pharmacokinetics

Figure 2: The Effects of Other Drugs on Dehydro-aripiprazole Pharmacokinetics

The effects of Abilify on the exposures of other drugs are summarized in Figure 3. A population PK analysis in patients with major depressive disorder showed no substantial change in plasma concentrations of fluoxetine (20 or 40 mg/day), paroxetine CR (37.5 or 50 mg/day), or sertraline (100 or 150 mg/day) dosed to steady-state. The steady-state plasma concentrations of fluoxetine and norfluoxetine increased by about 18% and 36%, respectively, and concentrations of paroxetine decreased by about 27%. The steady-state plasma concentrations of sertraline and desmethylsertraline were not substantially changed when these antidepressant therapies were coadministered with aripiprazole.

Figure 3: The Effects of Abilify on Pharmacokinetics of Other Drugs

Studies in Specific Populations

Exposures of aripiprazole and dehydro-aripiprazole in specific populations are summarized in Figure 4 and Figure 5, respectively. In addition, in pediatric patients (10 to 17 years of age) administered with Abilify (20 mg to 30 mg), the body weight corrected aripiprazole clearance was similar to the adults.

Figure 4: Effects of Intrinsic Factors on Aripiprazole Pharmacokinetics

Figure 5: Effects of Intrinsic Factors on Dehydro-aripiprazole Pharmacokinetics

INTRAMUSCULAR ADMINISTRATION

In two pharmacokinetic studies of aripiprazole injection administered intramuscularly to healthy subjects, the median times to the peak plasma concentrations were at 1 hour and 3 hours. A 5 mg intramuscular injection of aripiprazole had an absolute bioavailability of 100%. The geometric mean maximum concentration achieved after an intramuscular dose was on average 19% higher than the C max of the oral tablet. While the systemic exposure over 24 hours was generally similar between aripiprazole injection given intramuscularly and after oral tablet administration, the aripiprazole AUC in the first 2 hours after an intramuscular injection was 90% greater than the AUC after the same dose as a tablet. In stable patients with schizophrenia or schizoaffective disorder, the pharmacokinetics of aripiprazole after intramuscular administration were linear over a dose range of 1 mg to 45 mg. Although the metabolism of aripiprazole injection was not systematically evaluated, the intramuscular route of administration would not be expected to alter the metabolic pathways.

علم السموم غير السريري

التسرطن ، الطفرات ، ضعف الخصوبة

Carcinogenesis

Lifetime carcinogenicity studies were conducted in ICR mice, F344 rats, and Sprague-Dawley (SD) rats. Aripiprazole was administered for 2 years in the diet at doses of 1, 3, 10, and 30 mg/kg/day to ICR mice and 1, 3, and 10 mg/kg/day to F344 rats (0.2, 0.5, 2 and 5 times and 0.3, 1 and 3 times the MRHD of 30 mg/day based on mg/m 2 body surface area, respectively). In addition, SD rats were dosed orally for 2 years at 10, 20, 40, and 60 mg/kg/day, which are 3, 6, 13 and 19 times the MRHD based on mg/m 2 body surface area. Aripiprazole did not induce tumors in male mice or male rats. In female mice, the incidences of pituitary gland adenomas and mammary gland adenocarcinomas and adenoacanthomas were increased at dietary doses of 3 to 30 mg/kg/day (0.5 to 5 times the MRHD). In female rats, the incidence of mammary gland fibroadenomas was increased at a dietary dose of 10 mg/kg/day (3 times the MRHD); and the incidences of adrenocortical carcinomas and combined adrenocortical adenomas/carcinomas were increased at an oral dose of 60 mg/kg/day (19 times the MRHD).

An increase in mammary, pituitary, and endocrine pancreas neoplasms has been found in rodents after chronic administration of other antipsychotic drugs and is considered to be mediated by prolonged dopamine D 2-receptor antagonism and hyperprolactinemia. Serum prolactin was not measured in the aripiprazole carcinogenicity studies. However, increases in serum prolactin levels were observed in female mice in a 13-week dietary study at the doses associated with mammary gland and pituitary tumors. Serum prolactin was not increased in female rats in 4-week and 13-week dietary studies at the dose associated with mammary gland tumors. The relevance for human risk of the findings of prolactin-mediated endocrine tumors in rodents is unclear.

Mutagenesis

The mutagenic potential of aripiprazole was tested in the in vitro bacterial reverse-mutation assay, the in vitro bacterial DNA repair assay, the in vitro forward gene mutation assay in mouse lymphoma cells, the in vitro chromosomal aberration assay in Chinese hamster lung (CHL) cells, the in vivo micronucleus assay in mice, and the unscheduled DNA synthesis assay in rats. Aripiprazole and a metabolite (2,3-DCPP) were clastogenic in the in vitro chromosomal aberration assay in CHL cells with and without metabolic activation. The metabolite, 2,3-DCPP, increased numerical aberrations in the in vitro assay in CHL cells in the absence of metabolic activation. A positive response was obtained in the in vivo micronucleus assay in mice; however, the response was due to a mechanism not considered relevant to humans.

Impairment of Fertility

Female rats were treated orally with aripiprazole from 2 weeks prior to mating through gestation day 7 at doses of 2, 6, and 20 mg/kg/day, which are 0.6, 2, and 6 times the MRHD of 30 mg/day based on mg/m 2 body surface area. Estrus cycle irregularities and increased corpora lutea were seen at all doses, but no impairment of fertility was seen. Increased pre-implantation loss was seen at 2 and 6 times the MRHD, and decreased fetal weight was seen at 6 times the MRHD.

Male rats were treated orally with aripiprazole from 9 weeks prior to mating through mating at doses of 20, 40, and 60 mg/kg/day, which are 6, 13, and 19 times the MRHD of 30 mg/day based on mg/m 2 body surface area. Disturbances in spermatogenesis were seen at 19 times the MRHD and prostate atrophy was seen at 13 and 19 times the MRHD without impairment of fertility.

علم السموم و / أو علم الأدوية

Aripiprazole produced retinal degeneration in albino rats in a 26-week chronic toxicity study at a dose of 60 mg/kg/day and in a 2-year carcinogenicity study at doses of 40 and 60 mg/kg/day which are 13 and 19 times the MRHD of 30 mg/day based on mg/m 2 body surface area. Evaluation of the retinas of albino mice and of monkeys did not reveal evidence of retinal degeneration. Additional studies to further evaluate the mechanism have not been performed. The relevance of this finding to human risk is unknown.

الدراسات السريرية

Efficacy of the oral formulations of Abilify (aripiprazole) was established in the following adequate and well-controlled trials:

  • Four short-term trials and one maintenance trial in adult patients and one short-term trial in adolescents (ages 13 to 17) with schizophrenia [see Clinical Studies (14.1)]
  • Four short-term monotherapy trials and one 6-week adjunctive trial in adult patients and one short-term monotherapy trial in pediatric patients (ages 10 to 17) with manic or mixed episodes [see Clinical Studies (14.2)]
  • One maintenance monotherapy trial and in one maintenance adjunctive trial in adult patients with bipolar I disorder [see Clinical Studies (14.2)]
  • Two short-term trials in adult patients with MDD who had an inadequate response to antidepressant therapy during the current episode [see Clinical Studies (14.3)]
  • Two short-term trials in pediatric patients (ages 6 to 17 years) for the treatment of irritability associated with autistic disorder [see Clinical Studies (14.4)]
  • Two short-term trials in pediatric patients (ages 6 to 18 years) with Tourette’s disorder [see Clinical Studies (14.5)]

Efficacy of the injectable formulation of Abilify (aripiprazole) was established in the following adequate and well-controlled trials:

  • Three 24-hour trials in agitated adult patients with schizophrenia or manic/mixed episodes of bipolar I disorder [see Clinical Studies (14.6)]

Schizophrenia

الكبار

The efficacy of Abilify in the treatment of schizophrenia was evaluated in five short-term (4-week and 6-week), placebo-controlled trials of acutely relapsed inpatients who predominantly met DSM-III/IV criteria for schizophrenia. Four of the five trials were able to distinguish Abilify from placebo, but one study, the smallest, did not. Three of these studies also included an active control group consisting of either risperidone (one trial) or haloperidol (two trials), but they were not designed to allow for a comparison of Abilify and the active comparators.

In the four positive trials for Abilify, four primary measures were used for assessing psychiatric signs and symptoms. Efficacy was evaluated using the total score on the Positive and Negative Syndrome Scale (PANSS). The PANSS is a 30-item scale that measures positive symptoms of schizophrenia (7 items), negative symptoms of schizophrenia (7 items), and general psychopathology (16 items), each rated on a scale of 1 (absent) to 7 (extreme); total PANSS scores range from 30 to 210. The Clinical Global Impression (CGI) assessment reflects the impression of a skilled observer, fully familiar with the manifestations of schizophrenia, about the overall clinical state of the patient.

In a 4-week trial (n=414) comparing two fixed doses of Abilify (15 or 30 mg/day) to placebo, both doses of Abilify were superior to placebo in the PANSS total score (Study 1 in Table 26), PANSS positive subscale, and CGI-severity score. In addition, the 15 mg dose was superior to placebo in the PANSS negative subscale.

In a 4-week trial (n=404) comparing two fixed doses of Abilify (20 or 30 mg/day) to placebo, both doses of Abilify were superior to placebo in the PANSS total score (Study 2 in Table 26), PANSS positive subscale, PANSS negative subscale, and CGI-severity score.

In a 6-week trial (n=420) comparing three fixed doses of Abilify (10, 15, or 20 mg/day) to placebo, all three doses of Abilify were superior to placebo in the PANSS total score (Study 3 in Table 26), PANSS positive subscale, and the PANSS negative subscale.

In a 6-week trial (n=367) comparing three fixed doses of Abilify (2, 5, or 10 mg/day) to placebo, the 10 mg dose of Abilify was superior to placebo in the PANSS total score (Study 4 in Table 26), the primary outcome measure of the study. The 2 and 5 mg doses did not demonstrate superiority to placebo on the primary outcome measure.

Thus, the efficacy of 10, 15, 20, and 30 mg daily doses was established in two studies for each dose. Among these doses, there was no evidence that the higher dose groups offered any advantage over the lowest dose group of these studies.

An examination of population subgroups did not reveal any clear evidence of differential responsiveness on the basis of age, gender, or race.

A longer-term trial enrolled 310 inpatients or outpatients meeting DSM-IV criteria for schizophrenia who were, by history, symptomatically stable on other antipsychotic medications for periods of 3 months or longer. These patients were discontinued from their antipsychotic medications and randomized to Abilify 15 mg/day or placebo for up to 26 weeks of observation for relapse. Relapse during the double-blind phase was defined as CGI-Improvement score of ≥5 (minimally worse), scores ≥5 (moderately severe) on the hostility or uncooperativeness items of the PANSS, or ≥20% increase in the PANSS total score. Patients receiving Abilify 15 mg/day experienced a significantly longer time to relapse over the subsequent 26 weeks compared to those receiving placebo (Study 5 in Figure 6).

الأطفال المرضى

The efficacy of Abilify (aripiprazole) in the treatment of schizophrenia in pediatric patients (13 to 17 years of age) was evaluated in one 6-week, placebo-controlled trial of outpatients who met DSM-IV criteria for schizophrenia and had a PANSS score ≥70 at baseline. In this trial (n=302) comparing two fixed doses of Abilify (10 or 30 mg/day) to placebo, Abilify was titrated starting from 2 mg/day to the target dose in 5 days in the 10 mg/day treatment arm and in 11 days in the 30 mg/day treatment arm. Both doses of Abilify were superior to placebo in the PANSS total score (Study 6 in Table 26), the primary outcome measure of the study. The 30 mg/day dosage was not shown to be more efficacious than the 10 mg/day dose. Although maintenance efficacy in pediatric patients has not been systematically evaluated, maintenance efficacy can be extrapolated from adult data along with comparisons of aripiprazole pharmacokinetic parameters in adult and pediatric patients.

Table 26: Schizophrenia Studies

Study NumberTreatment GroupPrimary Efficacy Measure: PANSS
Mean Baseline Score (SD)LS Mean Change from Baseline (SE)Placebo-subtracted Difference * (95% CI)
SD: standard deviation; SE: standard error; LS Mean: least-squares mean; CI: unadjusted confidence interval.

*
Difference (drug minus placebo) in least-squares mean change from baseline.

Doses statistically significantly superior to placebo.

Study 1Abilify(15 mg/day) †98.5 (17.2)-15.5 (2.40)-12.6 (-18.9, -6.2)
Abilify(30 mg/day) †99.0 (19.2)-11.4 (2.39)-8.5 (-14.8, -2.1)
Placebo100.2 (16.5)-2.9 (2.36)
Study 2Abilify(20 mg/day) †92.6 (19.5)-14.5 (2.23)-9.6 (-15.4, -3.8)
Abilify(30 mg/day) †94.2 (18.5)-13.9 (2.24)-9.0 (-14.8, -3.1)
Placebo94.3 (18.5)-5.0 (2.17)
Study 3Abilify(10 mg/day) †92.7 (19.5)-15.0 (2.38)-12.7 (-19.00, -6.41)
Abilify(15 mg/day) †93.2 (21.6)-11.7 (2.38)-9.4 (-15.71, -3.08)
Abilify(20 mg/day) †92.5 (20.9)-14.4 (2.45)-12.1 (-18.53, -5.68)
Placebo92.3 (21.8)-2.3 (2.35)
Study 4Abilify (2 mg/day)90.7 (14.5)-8.2 (1.90)-2.9 (-8.29, 2.47)
Abilify (5 mg/day)92.0 (12.6)-10.6 (1.93)-5.2 (-10.7, 0.19)
Abilify(10 mg/day) †90.0 (11.9)-11.3 (1.88)-5.9 (-11.3, -0.58)
Placebo90.8 (13.3)-5.3 (1.97)
Study 6 (Pediatric, 13 to 17 years)Abilify(10 mg/day) †93.6 (15.7)-26.7 (1.91)-5.5 (-10.7, -0.21)
Abilify(30 mg/day) †94.0 (16.1)-28.6 (1.92)-7.4 (-12.7, -2.13)
Placebo94.6 (15.6)-21.2 (1.93)

Figure 6: Kaplan-Meier Estimation of Cumulative Proportion of Patients with Relapse (Schizophrenia Study 5)

Bipolar Disorder

Acute Treatment of Manic and Mixed Episodes

الكبار

Monotherapy

The efficacy of Abilify as monotherapy in the acute treatment of manic episodes was established in four 3-week, placebo-controlled trials in hospitalized patients who met the DSM-IV criteria for bipolar I disorder with manic or mixed episodes. These studies included patients with or without psychotic features and two of the studies also included patients with or without a rapid-cycling course.

The primary instrument used for assessing manic symptoms was the Young Mania Rating Scale (Y-MRS), an 11-item clinician-rated scale traditionally used to assess the degree of manic symptomatology in a range from 0 (no manic features) to 60 (maximum score). A key secondary instrument included the Clinical Global Impression-Bipolar (CGI-BP) Scale.

In the four positive, 3-week, placebo-controlled trials (n=268; n=248; n=480; n=485) which evaluated Abilify in a range of 15 mg to 30 mg, once daily (with a starting dose of 30 mg/day in two studies and 15 mg/day in two studies), Abilify was superior to placebo in the reduction of Y-MRS total score (Studies 1 to 4 in Table 27) and CGI-BP Severity of Illness score (mania). In the two studies with a starting dose of 15 mg/day, 48% and 44% of patients were on 15 mg/day at endpoint. In the two studies with a starting dose of 30 mg/day, 86% and 85% of patients were on 30 mg/day at endpoint.

Adjunctive Therapy

The efficacy of adjunctive Abilify with concomitant lithium or valproate in the treatment of manic or mixed episodes was established in a 6-week, placebo-controlled study (n=384) with a 2-week lead-in mood stabilizer monotherapy phase in adult patients who met DSM-IV criteria for bipolar I disorder. This study included patients with manic or mixed episodes and with or without psychotic features.

Patients were initiated on open-label lithium (0.6 to 1.0 mEq/L) or valproate (50 to 125 μg/mL) at therapeutic serum levels, and remained on stable doses for 2 weeks. At the end of 2 weeks, patients demonstrating inadequate response (Y-MRS total score ≥16 and ≤25% improvement on the Y-MRS total score) to lithium or valproate were randomized to receive either Abilify (15 mg/day or an increase to 30 mg/day as early as day 7) or placebo as adjunctive therapy with open-label lithium or valproate. In the 6-week, placebo-controlled phase, adjunctive Abilify starting at 15 mg/day with concomitant lithium or valproate (in a therapeutic range of 0.6 to 1.0 mEq/L or 50 to 125 μg/mL, respectively) was superior to lithium or valproate with adjunctive placebo in the reduction of the Y-MRS total score (Study 5 in Table 27) and CGI-BP Severity of Illness score (mania). Seventy-one percent of the patients coadministered valproate and 62% of the patients coadministered lithium were on 15 mg/day at 6-week endpoint.

الأطفال المرضى

The efficacy of Abilify in the treatment of bipolar I disorder in pediatric patients (10 to 17 years of age) was evaluated in one 4-week, placebo-controlled trial (n=296) of outpatients who met DSM-IV criteria for bipolar I disorder manic or mixed episodes with or without psychotic features and had a Y-MRS score ≥20 at baseline. This double-blind, placebo-controlled trial compared two fixed doses of Abilify (10 or 30 mg/day) to placebo. The Abilify dose was started at 2 mg/day, which was titrated to 5 mg/day after 2 days, and to the target dose in 5 days in the 10 mg/day treatment arm, and in 13 days in the 30 mg/day treatment arm. Both doses of Abilify were superior to placebo in change from baseline to week 4 on the Y-MRS total score (Study 6 in Table 27).

Table 27: Bipolar Studies

Study NumberTreatment GroupPrimary Efficacy Measure: Y-MRS
Mean Baseline Score (SD)LS Mean Change from Baseline (SE)Placebo-subtracted Difference * (95% CI)
SD: standard deviation; SE: standard error; LS Mean: least-squares mean; CI: unadjusted confidence interval.

*
Difference (drug minus placebo) in least-squares mean change from baseline.

Doses statistically significantly superior to placebo.

Study 1Abilify (30/15 mg/day) †29.0 (5.9)-12.52 (1.05)-5.33 (-7.90, -2.76)
Placebo28.5 (4.6)-7.19 (1.07)
Study 2Abilify (30/15 mg/day) †27.8 (5.7)-8.15 (1.23)-4.80 (-7.80, -1.80)
Placebo29.1 (6.9)-3.35 (1.22)
Study 3Abilify (15 to 30 mg/day) †28.5 (5.6)-12.64 (0.84)-3.63 (-5.75, -1.51)
Placebo28.9 (5.9)9.01 (0.81)
Study 4Abilify (15 to 30 mg/day) †28.0 (5.8)-11.98 (0.80)-2.28 (-4.44, -0.11)
Placebo28.3 (5.8)-9.70 (0.83)
Study 5Abilify (15 or 30 mg/day) † + Lithium/Valproate23.2 (5.7)-13.31 (0.50)-2.62 (-4.29, -0.95)
Placebo + Lithium/Valproate23.0 (4.9)-10.70 (0.69)
Study 6
(Pediatric, 10 to 17 years)
Abilify (10 mg/day) †29.8 (6.5)-14.2 (0.89)-5.99 (-8.49, -3.50)
Abilify (30 mg/day) †29.5 (6.3)-16.5 (0.87)-8.26 (-10.7, -5.77)
Placebo30.7 (6.8)-8.2 (0.91)

Maintenance Treatment of Bipolar I Disorder

Monotherapy Maintenance Therapy

A maintenance trial was conducted in adult patients meeting DSM-IV criteria for bipolar I disorder with a recent manic or mixed episode who had been stabilized on open-label Abilify and who had maintained a clinical response for at least 6 weeks. The first phase of this trial was an open-label stabilization period in which inpatients and outpatients were clinically stabilized and then maintained on open-label Abilify (15 or 30 mg/day, with a starting dose of 30 mg/day) for at least 6 consecutive weeks. One hundred sixty-one outpatients were then randomized in a double-blind fashion, to either the same dose of Abilify they were on at the end of the stabilization and maintenance period or placebo and were then monitored for manic or depressive relapse. During the randomization phase, Abilify was superior to placebo on time to the number of combined affective relapses (manic plus depressive), the primary outcome measure for this study (Study 7 in Figure 7). A total of 55 mood events were observed during the double-blind treatment phase. Nineteen were from the Abilify group and 36 were from the placebo group. The number of observed manic episodes in the Abilify group (6) were fewer than that in the placebo group (19), while the number of depressive episodes in the Abilify group (9) was similar to that in the placebo group (11).

An examination of population subgroups did not reveal any clear evidence of differential responsiveness on the basis of age and gender; however, there were insufficient numbers of patients in each of the ethnic groups to adequately assess inter-group differences.

Figure 7: Kaplan-Meier Estimation of Cumulative Proportion of Patients with Relapse (Bipolar Study 7)

Adjunctive Maintenance Therapy

An adjunctive maintenance trial was conducted in adult patients meeting DSM-IV criteria for bipolar I disorder with a recent manic or mixed episode. Patients were initiated on open-label lithium (0.6 to 1.0 mEq/L) or valproate (50 to 125 μg/mL) at therapeutic serum levels, and remained on stable doses for 2 weeks. At the end of 2 weeks, patients demonstrating inadequate response (Y-MRS total score ≥16 and ≤35% improvement on the Y-MRS total score) to lithium or valproate received Abilify with a starting dose of 15 mg/day with the option to increase to 30 mg or reduce to 10 mg as early as day 4, as adjunctive therapy with open-label lithium or valproate. Prior to randomization, patients on the combination of single-blind Abilify and lithium or valproate were required to maintain stability (Y-MRS and MADRS total scores ≤12) for 12 consecutive weeks. Three hundred thirty-seven patients were then randomized in a double-blind fashion, to either the same dose of Abilify they were on at the end of the stabilization period or placebo plus lithium or valproate and were then monitored for manic, mixed, or depressive relapse for a maximum of 52 weeks. Abilify was superior to placebo on the primary endpoint, time from randomization to relapse to any mood event (Study 8 in Figure 8). A mood event was defined as hospitalization for a manic, mixed, or depressive episode, study discontinuation due to lack of efficacy accompanied by Y-MRS score >16 and/or a MADRS >16, or an SAE of worsening disease accompanied by Y-MRS score >16 and/or a MADRS >16. A total of 68 mood events were observed during the double-blind treatment phase. Twenty-five were from the Abilify group and 43 were from the placebo group. The number of observed manic episodes in the Abilify group (7) were fewer than that in the placebo group (19), while the number of depressive episodes in the Abilify group (14) was similar to that in the placebo group (18). The Kaplan-Meier curves of the time from randomization to relapse to any mood event during the 52-week, double-blind treatment phase for Abilify and placebo groups are shown in Figure 8.

Figure 8: Kaplan-Meier Estimation of Cumulative Proportion of Patients with Relapse to Any Mood Event (Bipolar Study 8)

An examination of population subgroups did not reveal any clear evidence of differential responsiveness on the basis of age and gender; however, there were insufficient numbers of patients in each of the ethnic groups to adequately assess inter-group differences.

Adjunctive Treatment of Major Depressive Disorder

الكبار

The efficacy of Abilify in the adjunctive treatment of major depressive disorder (MDD) was demonstrated in two short-term (6-week), placebo-controlled trials of adult patients meeting DSM-IV criteria for MDD who had had an inadequate response to prior antidepressant therapy (1 to 3 courses) in the current episode and who had also demonstrated an inadequate response to 8 weeks of prospective antidepressant therapy (paroxetine controlled-release, venlafaxine extended-release, fluoxetine, escitalopram, or sertraline). Inadequate response for prospective treatment was defined as less than 50% improvement on the 17-item version of the Hamilton Depression Rating Scale (HAMD17), minimal HAMD17 score of 14, and a Clinical Global Impressions Improvement rating of no better than minimal improvement. Inadequate response to prior treatment was defined as less than 50% improvement as perceived by the patient after a minimum of 6 weeks of antidepressant therapy at or above the minimal effective dose.

The primary instrument used for assessing depressive symptoms was the Montgomery-Asberg Depression Rating Scale (MADRS), a 10-item clinician-rated scale used to assess the degree of depressive symptomatology. The key secondary instrument was the Sheehan Disability Scale (SDS), a 3-item self-rated instrument used to assess the impact of depression on three domains of functioning with each item scored from 0 (not at all) to 10 (extreme).

In the two trials (n=381, n=362), Abilify was superior to placebo in reducing mean MADRS total scores (Studies 1, 2 in Table 28). In one study, Abilify was also superior to placebo in reducing the mean SDS score.

In both trials, patients received Abilify adjunctive to antidepressants at a dose of 5 mg/day. Based on tolerability and efficacy, doses could be adjusted by 5 mg increments, one week apart. Allowable doses were: 2, 5, 10, 15 mg/day, and for patients who were not on potent CYP2D6 inhibitors fluoxetine and paroxetine, 20 mg/day. The mean final dose at the end point for the two trials was 10.7 and 11.4 mg/day.

An examination of population subgroups did not reveal evidence of differential response based on age, choice of prospective antidepressant, or race. With regard to gender, a smaller mean reduction on the MADRS total score was seen in males than in females.

Table 28: Adjunctive Treatment of Major Depressive Disorder Studies

Study NumberTreatment GroupPrimary Efficacy Measure: MADRS
Mean Baseline Score (SD)LS Mean Change from Baseline (SE)Placebo-subtracted Difference * (95% CI)
SD: standard deviation; SE: standard error; LS Mean: least-squares mean; CI: unadjusted confidence interval.

*
Difference (drug minus placebo) in least-squares mean change from baseline.

Doses statistically significantly superior to placebo.

Study 1Abilify (5 to 20 mg/day) † + Antidepressant25.2 (6.2)-8.49 (0.66)-2.84 (-4.53, -1.15)
Placebo + Antidepressant27.0 (5.5)-5.65 (0.64)
Study 2Abilify (5 to 20 mg/day) † + Antidepressant26.0 (6.0)-8.78 (0.63)-3.01 (-4.66, -1.37)
Placebo + Antidepressant26.0 (6.5)-5.77 (0.67)

Irritability Associated with Autistic Disorder

الأطفال المرضى

The efficacy of Abilify (aripiprazole) in the treatment of irritability associated with autistic disorder was established in two 8-week, placebo-controlled trials in pediatric patients (6 to 17 years of age) who met the DSM-IV criteria for autistic disorder and demonstrated behaviors such as tantrums, aggression, self-injurious behavior, or a combination of these problems. Over 75% of these subjects were under 13 years of age.

Efficacy was evaluated using two assessment scales: the Aberrant Behavior Checklist (ABC) and the Clinical Global Impression-Improvement (CGI-I) scale. The primary outcome measure in both trials was the change from baseline to endpoint in the Irritability subscale of the ABC (ABC-I). The ABC-I subscale measured symptoms of irritability in autistic disorder.

The results of these trials are as follows:

In one of the 8-week, placebo-controlled trials, children and adolescents with autistic disorder (n=98), aged 6 to 17 years, received daily doses of placebo or Abilify 2 to 15 mg/day. Abilify, starting at 2 mg/day with increases allowed up to 15 mg/day based on clinical response, significantly improved scores on the ABC-I subscale and on the CGI-I scale compared with placebo. The mean daily dose of Abilify at the end of 8-week treatment was 8.6 mg/day (Study 1 in Table 29).

In the other 8-week, placebo-controlled trial in children and adolescents with autistic disorder (n=218), aged 6 to 17 years, three fixed doses of Abilify (5 mg/day, 10 mg/day, or 15 mg/day) were compared to placebo. Abilify dosing started at 2 mg/day and was increased to 5 mg/day after one week. After a second week, it was increased to 10 mg/day for patients in the 10 and 15 mg dose arms, and after a third week, it was increased to 15 mg/day in the 15 mg/day treatment arm (Study 2 in Table 29). All three doses of Abilify significantly improved scores on the ABC-I subscale compared with placebo.

Table 29: Irritability Associated with Autistic Disorder Studies (Pediatric)

Study NumberTreatment GroupPrimary Efficacy Measure: ABC-I
Mean Baseline Score (SD)LS Mean Change from Baseline (SE)Placebo-subtracted Difference * (95% CI)
SD: standard deviation; SE: standard error; LS Mean: least-squares mean; CI: unadjusted confidence interval.

*
Difference (drug minus placebo) in least-squares mean change from baseline.

Doses statistically significantly superior to placebo.

Study 1Abilify (2 to 15 mg/day) †29.6 (6.37)-12.9 (1.44)-7.9 (-11.7, -4.1)
Placebo30.2 (6.52)-5.0 (1.43)
Study 2Abilify (5 mg/day) †28.6 (7.56)-12.4 (1.36)-4.0 (-7.7, -0.4)
Abilify (10 mg/day) †28.2 (7.36)-13.2 (1.25)-4.8 (-8.4, -1.3)
Abilify (15 mg/day) †28.9 (6.41)-14.4 (1.31)-6.0 (-9.6, -2.3)
Placebo28.0 (6.89)-8.4 (1.39)

Tourette’s Disorder

الأطفال المرضى

The efficacy of Abilify (aripiprazole) in the treatment of Tourette’s disorder was established in one 8-week (7 to 17 years of age) and one 10-week (6 to 18 years of age), placebo-controlled trials in pediatric patients (6 to 18 years of age) who met the DSM-IV criteria for Tourette’s disorder and had a Total Tic score (TTS) ≥20 to 22 on the Yale Global Tic Severity Scale (YGTSS). The YGTSS is a fully validated scale designed to measure current tic severity. Efficacy was evaluated using two assessment scales: 1) the Total Tic score (TTS) of the YGTSS and 2) the Clinical Global Impressions Scale for Tourette’s Syndrome (CGI-TS), a clinician-determined summary measure that takes into account all available patient information. Over 65% of these patients were under 13 years of age.

The primary outcome measure in both trials was the change from baseline to endpoint in the TTS of the YGTSS. Ratings for the TTS are made along 5 different dimensions on a scale of 0 to 5 for motor and vocal tics each. Summation of these 10 scores provides a TTS (i.e., 0 to 50).

The results of these trials are as follows:

In the 8-week, placebo-controlled, fixed-dose trial, children and adolescents with Tourette’s disorder (n=133), aged 7 to 17 years, were randomized 1:1:1 to low dose Abilify, high dose Abilify, or placebo. The target doses for the low and high dose Abilify groups were based on weight. Patients <50 kg in the low dose Abilify group started at 2 mg per day with a target dose of 5 mg per day after 2 days. Patients ≥50 kg in the low dose Abilify group, started at 2 mg per day increased to 5 mg per day after 2 days, with a subsequent increase to a target dose of 10 mg per day at day 7. Patients <50 kg in the high dose Abilify group started at 2 mg per day increased to 5 mg per day after 2 days, with a subsequent increase to a target dose of 10 mg per day at day 7. Patients ≥50 kg in the high dose Abilify group, started at 2 mg per day increased to 5 mg per day after 2 days, with a subsequent increase to a dose of 10 mg per day at day 7 and were allowed weekly increases of 5 mg per day up to a target dose 20 mg per day at Day 21. Abilify (both high and low dose groups) demonstrated statistically significantly improved scores on the YGTSS TTS (Study 1 in Table 30) and on the CGI-TS scale compared with placebo. The estimated improvements on the YGTSS TTS over the course of the study are displayed in Figure 9.

Figure 9: Least Square Means of Change from Baseline in YGTSS TTS by Week (Tourette’s Disorder Study 1)

In the 10-week, placebo-controlled, flexible-dose trial in children and adolescents with Tourette’s disorder (n=61), aged 6 to 18 years, patients received daily doses of placebo or Abilify, starting at 2 mg/day with increases allowed up to 20 mg/day based on clinical response. Abilify demonstrated statistically significantly improved scores on the YGTSS TTS scale compared with placebo (Study 2 in Table 30). The mean daily dose of Abilify at the end of 10-week treatment was 6.54 mg/day.

Table 30: Tourette’s Disorder Studies (Pediatric)

Study NumberTreatment GroupPrimary Efficacy Measure: YGTSS TTS
Mean Baseline Score (SD)LS Mean Change from Baseline (SE)Placebo-subtracted Difference * (95% CI)
SD: standard deviation; SE: standard error; LS Mean: least-squares mean; CI: unadjusted confidence interval.

*
Difference (drug minus placebo) in least-squares mean change from baseline.

Doses statistically significantly superior to placebo.

Study 1Abilify (low dose) †29.2 (5.63)-13.4 (1.59)-6.3 (-10.2, -2.3)
Abilify (high dose) †31.2 (6.40)-16.9 (1.61)-9.9 (-13.8, -5.9)
Placebo30.7 (5.95)-7.1 (1.55)
Study 2Abilify (2 to 20 mg/day) †28.3 (5.51)-15.0 (1.51)-5.3 (-9.8, -0.9)
Placebo29.5 (5.60)-9.6 (1.64)

Agitation Associated with Schizophrenia or Bipolar Mania

The efficacy of intramuscular Abilify for injection for the treatment of agitation was established in three short-term (24-hour), placebo-controlled trials in agitated inpatients from two diagnostic groups: schizophrenia and bipolar I disorder (manic or mixed episodes, with or without psychotic features). Each of the trials included a single active comparator treatment arm of either haloperidol injection (schizophrenia studies) or lorazepam injection (bipolar mania study). Patients could receive up to three injections during the 24-hour treatment periods; however, patients could not receive the second injection until after the initial 2-hour period when the primary efficacy measure was assessed. Patients enrolled in the trials needed to be: (1) judged by the clinical investigators as clinically agitated and clinically appropriate candidates for treatment with intramuscular medication, and (2) exhibiting a level of agitation that met or exceeded a threshold score of ≥15 on the five items comprising the Positive and Negative Syndrome Scale (PANSS) Excited Component (i.e., poor impulse control, tension, hostility, uncooperativeness, and excitement items) with at least two individual item scores ≥4 using a 1 to 7 scoring system (1= absent, 4= moderate, 7= extreme). In the studies, the mean baseline PANSS Excited Component score was 19, with scores ranging from 15 to 34 (out of a maximum score of 35), thus suggesting predominantly moderate levels of agitation with some patients experiencing mild or severe levels of agitation. The primary efficacy measure used for assessing agitation signs and symptoms in these trials was the change from baseline in the PANSS Excited Component at 2 hours post-injection. A key secondary measure was the Clinical Global Impression of Improvement (CGI-I) Scale. The results of the trials follow:

In a placebo-controlled trial in agitated inpatients predominantly meeting DSM-IV criteria for schizophrenia (n=350), four fixed Abilify injection doses of 1 mg, 5.25 mg, 9.75 mg, and 15 mg were evaluated. At 2 hours post-injection, the 5.25 mg, 9.75 mg, and 15 mg doses were statistically superior to placebo in the PANSS Excited Component (Study 1 in Table 31) and on the CGI-I Scale.

In a second placebo-controlled trial in agitated inpatients predominantly meeting DSM-IV criteria for schizophrenia (n=445), one fixed Abilify injection dose of 9.75 mg was evaluated. At 2 hours post-injection, Abilify for injection was statistically superior to placebo in the PANSS Excited Component (Study 2 in Table 31) and on the CGI-I Scale.

In a placebo-controlled trial in agitated inpatients meeting DSM-IV criteria for bipolar I disorder (manic or mixed) (n=291), two fixed Abilify injection doses of 9.75 mg and 15 mg were evaluated. At 2 hours post-injection, both doses were statistically superior to placebo in the PANSS Excited Component (Study 3 in Table 31).

Examination of population subsets (age, race, and gender) did not reveal any differential responsiveness on the basis of these subgroupings.

Table 31: Agitation Associated with Schizophrenia or Bipolar Mania Studies

Study NumberTreatment GroupPrimary Efficacy Measure: PANSS Excited Component
Mean Baseline Score (SD)LS Mean Change from Baseline (SE)Placebo-subtracted Difference * (95% CI)
SD: standard deviation; SE: standard error; LS Mean: least-squares mean; CI: unadjusted confidence interval.

*
Difference (drug minus placebo) in least-squares mean change from baseline.

Doses statistically significantly superior to placebo.

Agitation Associated with Schizophrenia
Study 1Abilify (1 mg)19.16 (3.26)-4.47 (0.72)-1.19 (-2.96, 0.59)
Abilify (5.25 mg) †19.41 (3.31)-5.65 (0.68)-2.37 (-4.10, -0.63)
Abilify (9.75 mg) †19.42 (2.80)-6.69 (0.72)-3.40 (-5.18, -1.62)
Abilify (15 mg) †19.34 (2.38)-5.72 (0.72)-2.44 (-4.21, -0.68)
Placebo19.18 (2.95)-3.28 (0.70)
Study 2Abilify (9.75 mg) †18.82 (2.67)-7.27 (0.59)-2.48 (-3.77, -1.19)
Placebo18.74 (2.71)-4.78 (0.69)
Agitation Associated with Bipolar Mania
Study 3Abilify (9.75 mg) †18.77 (2.45)-8.74 (0.57)-2.99 (-4.53, -1.44)
Abilify (15 mg) †18.29 (2.49)-8.67 (0.57)-2.91 (-4.44, -1.38)
Placebo17.95 (2.63)-5.76 (0.58)

كيفية التزويد / التخزين والتداول

How Supplied

Abilify ® (aripiprazole) Tablets have markings on one side and are available in the strengths and packages listed in Table 32.

Table 32: Abilify Tablet Presentations

Tablet StrengthTablet Color/ShapeTablet MarkingsPack SizeNDC Code
2 mggreen
modified rectangle
“A-006” and “2”Bottle of 3059148-006-13
5 mgblue
modified rectangle
“A-007” and “5”Bottle of 30
Blister of 100
59148-007-13
59148-007-35
10 mgpink
modified rectangle
“A-008” and “10”Bottle of 30
Blister of 100
59148-008-13
59148-008-35
15 mgyellow
round
“A-009” and “15”Bottle of 30
Blister of 100
59148-009-13
59148-009-35
20 mgأبيض
round
“A-010” and “20”Bottle of 30
Blister of 100
59148-010-13
59148-010-35
30 mgpink
round
“A-011” and “30”Bottle of 30
Blister of 100
59148-011-13
59148-011-35

Abilify DISCMELT ® (aripiprazole) Orally Disintegrating Tablets are round tablets with markings on either side. Abilify DISCMELT is available in the strengths and packages listed in Table 33.

Table 33: Abilify DISCMELT Orally Disintegrating Tablet Presentations

Tablet StrengthTablet ColorTablet MarkingsPack SizeNDC Code
10 mgpink (with scattered specks)“A” and “640”
“10”
Blister of 3059148-640-23
15 mgyellow (with scattered specks)“A” and “641”
“15”
Blister of 3059148-641-23

Abilify ® (aripiprazole) Oral Solution (1 mg/mL) is supplied in child-resistant bottles along with a calibrated oral dosing cup. Abilify Oral Solution is available as follows:

150 mL bottle     NDC 59148-013-15

Abilify ® (aripiprazole) Injection for intramuscular use is available as a ready-to-use, 9.75 mg/1.3 mL (7.5 mg/mL) solution in clear, Type 1 glass vials as follows:

9.75 mg/1.3 mL single-dose vial     NDC 59148-016-65

Storage

أجهزة لوحية

Store at 25°C (77°F); excursions permitted between 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].

Oral Solution

Store at 25°C (77°F); excursions permitted between 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Opened bottles of Abilify Oral Solution can be used for up to 6 months after opening, but not beyond the expiration date on the bottle. The bottle and its contents should be discarded after the expiration date.

Injection

Store at 25ºC (77°F); excursions permitted between 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Protect from light by storing in the original container. Retain in carton until time of use.

Patient Counseling Information

Advise the patient to read the FDA-approved patient labeling ( Medication Guide ).

Discuss the following issues with patients prescribed Abilify:

Clinical Worsening of Depression and Suicide Risk

Patients, their families, and their caregivers should be encouraged to be alert to the emergence of anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, mania, other unusual changes in behavior, worsening of depression, and suicidal ideation, especially early during antidepressant treatment and when the dose is adjusted up or down. Families and caregivers of patients should be advised to look for the emergence of such symptoms on a day-to-day basis, since changes may be abrupt. Such symptoms should be reported to the patient’s prescriber or health professional, especially if they are severe, abrupt in onset, or were not part of the patient’s presenting symptoms. Symptoms such as these may be associated with an increased risk for suicidal thinking and behavior and indicate a need for very close monitoring and possibly changes in the medication [see Warnings and Precautions (5.3)] .

Prescribers or other health professionals should inform patients, their families, and their caregivers about the benefits and risks associated with treatment with Abilify and should counsel them in its appropriate use. A patient Medication Guide including information about “Antidepressant Medicines, Depression and other Serious Mental Illness, and Suicidal Thoughts or Actions” is available for Abilify. The prescriber or health professional should instruct patients, their families, and their caregivers to read the Medication Guide and should assist them in understanding its contents. Patients should be given the opportunity to discuss the contents of the Medication Guide and to obtain answers to any questions they may have. It should be noted that Abilify is not approved as a single agent for treatment of depression and has not been evaluated in pediatric major depressive disorder.

Pathological Gambling and Other Compulsive Behaviors

Advise patients and their caregivers of the possibility that they may experience compulsive urges to shop, intense urges to gamble, compulsive sexual urges, binge eating and/or other compulsive urges and the inability to control these urges while taking aripiprazole. In some cases, but not all, the urges were reported to have stopped when the dose was reduced or stopped [see Warnings and Precautions (5.7)].

Use of Orally Disintegrating Tablet

Do not open the blister until ready to administer. For single tablet removal, open the package and peel back the foil on the blister to expose the tablet. Do not push the tablet through the foil because this could damage the tablet. Immediately upon opening the blister, using dry hands, remove the tablet and place the entire Abilify DISCMELT Orally Disintegrating Tablet on the tongue. Tablet disintegration occurs rapidly in saliva. It is recommended that Abilify DISCMELT be taken without liquid. However, if needed, it can be taken with liquid. Do not attempt to split the tablet.

Interference with Cognitive and Motor Performance

Because Abilify may have the potential to impair judgment, thinking, or motor skills, patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that Abilify therapy does not affect them adversely [see Warnings and Precautions (5.12)] .

Concomitant Medication

Patients should be advised to inform their physicians if they are taking, or plan to take, any prescription or over-the-counter drugs, since there is a potential for interactions [see Drug Interactions (7)] .

Heat Exposure and Dehydration

Patients should be advised regarding appropriate care in avoiding overheating and dehydration [see Warnings and Precautions (5.13)] .

Sugar Content

Patients should be advised that each mL of Abilify Oral Solution contains 400 mg of sucrose and 200 mg of fructose.

حمل

Advise patients to notify their healthcare provider if they become pregnant or intend to become pregnant during treatment with Abilify. Advise patients that Abilify may cause extrapyramidal and/or withdrawal symptoms (agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, and feeding disorder) in a neonate. Advise patients that there is a pregnancy registry that monitors pregnancy outcomes in women exposed to Abilify during pregnancy [see Use in Specific Populations (8.1)].

Phenylketonurics

Phenylalanine is a component of aspartame. Each Abilify DISCMELT Orally Disintegrating Tablet contains the following amounts: 10 mg, 1.12 mg phenylalanine and 15 mg, 1.68 mg phenylalanine.

Tablets manufactured by Otsuka Pharmaceutical Co., Ltd., Tokyo, 101-8535 Japan

Orally Disintegrating Tablets, Oral Solution, and Injection manufactured by Bristol-Myers Squibb Company, Princeton, NJ 08543 USA

Distributed and marketed by Otsuka America Pharmaceutical, Inc., Rockville, MD 20850 USA

Abilify is a trademark of Otsuka Pharmaceutical Company.

©2020, Otsuka Pharmaceutical Co., Ltd., Tokyo, 101-8535 Japan

This Medication Guide has been approved by the U.S. Food and Drug AdministrationRevised: 02/2020

MEDICATION GUIDE

Abilify ® (a BIL ĭ fī)
(aripiprazole)
أجهزة لوحية

Abilify ® (a BIL ĭ fī)
(aripiprazole)
Orally Disintegrating Tablets

Abilify ® (a BIL ĭ fī)
(aripiprazole)
Oral Solution

Abilify ® (a BIL ĭ fī)
(aripiprazole)
Injection, for intramuscular use

What is the most important information I should know about Abilify?

(For other side effects, also see ” What are the possible side effects of Abilify?”)

Serious side effects may happen when you take Abilify, including:

  • Increased risk of death in elderly patients with dementia-related psychosis: Medicines like Abilify can raise the risk of death in elderly people who have lost touch with reality (psychosis) due to confusion and memory loss (dementia). Abilify is not approved for the treatment of patients with dementia-related psychosis.

  • Risk of suicidal thoughts or actions: Antidepressant medicines, depression and other serious mental illnesses, and suicidal thoughts or actions:

    • Antidepressant medicines may increase suicidal thoughts or actions in some children, teenagers, and young adults within the first few months of treatment.
    • Depression and other serious mental illnesses are the most important causes of suicidal thoughts and actions. Some people may have a particularly high risk of having suicidal thoughts or actions. These include people who have (or have a family history of) bipolar illness (also called manic-depressive illness) or suicidal thoughts or actions.

    • How can I watch for and try to prevent suicidal thoughts and actions in myself or a family member?

      • Pay close attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings. This is very important when an antidepressant medicine is started or when the dose is changed.
      • Call the healthcare provider right away to report new or sudden changes in mood, behavior, thoughts, or feelings.
      • Keep all follow-up visits with the healthcare provider as scheduled. Call the healthcare provider between visits as needed, especially if you have concerns about symptoms.

Call a healthcare provider right away if you or your family member has any of the following symptoms, especially if they are new, worse, or worry you:

  • thoughts about suicide or dying
  • attempts to commit suicide
  • new or worse depression
  • new or worse anxiety
  • feeling very agitated or restless
  • panic attacks
  • trouble sleeping (insomnia)
  • new or worse irritability
  • acting aggressive, being angry, or violent
  • acting on dangerous impulses
  • an extreme increase in activity and talking (mania)
  • other unusual changes in behavior or mood

What else do I need to know about antidepressant medicines?

  • Never stop an antidepressant medicine without first talking to a healthcare provider. Stopping an antidepressant medicine suddenly can cause other symptoms.

  • Antidepressants are medicines used to treat depression and other illnesses. It is important to discuss all the risks of treating depression and also the risks of not treating it. Patients and their families or other caregivers should discuss all treatment choices with the healthcare provider, not just the use of antidepressants.

  • Antidepressant medicines have other side effects. Talk to the healthcare provider about the side effects of the medicine prescribed for you or your family member.

  • Antidepressant medicines can interact with other medicines. Know all of the medicines that you or your family member takes. Keep a list of all medicines to show the healthcare provider. Do not start new medicines without first checking with your healthcare provider.

  • Not all antidepressant medicines prescribed for children are FDA approved for use in children. Talk to your child’s healthcare provider for more information.

What is Abilify?

  • Abilify Oral Tablets, Orally-Disintegrating Tablets, and Oral Solution are prescription medicines used to treat:

    • schizophrenia
    • manic or mixed episodes that happen with bipolar I disorder
    • major depressive disorder (MDD) when Abilify is used with antidepressant medicines
    • irritability associated with autistic disorder
    • Tourette’s disorder
  • Abilify Injection is a prescription medicine used to treat:

    • agitation associated with schizophrenia or bipolar mania

It is not known if Abilify is safe or effective in children:

  • under 13 years of age with schizophrenia
  • under 10 years of age with bipolar I disorder
  • under 6 years of age with irritability associated with autistic disorder
  • under 6 years of age with Tourette’s disorder

Do not take Abilify if you are allergic to aripiprazole or any of the ingredients in Abilify. See the end of this Medication Guide for a complete list of ingredients in Abilify.

Before taking Abilify, tell your healthcare provider about all your medical conditions, including if you have or had:

  • diabetes or high blood sugar in you or your family; your healthcare provider should check your blood sugar before you start Abilify and also during therapy.
  • seizures (convulsions).
  • low or high blood pressure.
  • heart problems or stroke.
  • pregnancy or plans to become pregnant. It is not known if Abilify will harm your unborn baby.
    • If you become pregnant while receiving Abilify, talk to your healthcare provider about registering with the National Pregnancy Registry for Atypical Antipsychotics. You can register by calling 1-866-961-2388 or go to http://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/
  • breast-feeding or plans to breast-feed. Abilify passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you receive Abilify.
  • low white blood cell count.
  • phenylketonuria. Abilify DISCMELT Orally Disintegrating Tablets contain phenylalanine.

Tell your healthcare provider about all the medicines that you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
Abilify and other medicines may affect each other causing possible serious side effects. Abilify may affect the way other medicines work, and other medicines may affect how Abilify works.
Your healthcare provider can tell you if it is safe to take Abilify with your other medicines. Do not start or stop any medicines while taking Abilify without talking to your healthcare provider first. Know the medicines you take. Keep a list of your medicines to show your healthcare provider and pharmacist when you get a new medicine.

How should I take Abilify?

  • Take Abilify exactly as your healthcare provider tells you to take it. Do not change the dose or stop taking Abilify yourself.
  • Abilify can be taken with or without food.
  • Abilify tablets should be swallowed whole.
  • If you miss a dose of Abilify, take the missed dose as soon as you remember. If it is almost time for the next dose, just skip the missed dose and take your next dose at the regular time. Do not take two doses of Abilify at the same time.
  • If you have been prescribed Abilify DISCMELT, take it as follows:
    • Do not open the blister until ready to take the DISCMELT tablet.
    • To remove one DISCMELT tablet, open the package and peel back the foil on the blister to expose the tablet.
    • Do not push the tablet through the foil because this could damage the tablet.
    • Immediately upon opening the blister, using dry hands, remove the tablet and place the entire Abilify DISCMELT Orally Disintegrating Tablet on the tongue.
    • Tablet disintegration occurs rapidly in saliva. It is recommended that Abilify DISCMELT be taken without liquid. However, if needed, it can be taken with liquid.
    • Do not attempt to split the DISCMELT tablet.
  • If you take too much Abilify, call your healthcare provider or poison control center at 1-800-222-1222 right away, or go to the nearest hospital emergency room.

What should I avoid while taking Abilify?

  • Do not drive, operate heavy machinery, or do other dangerous activities until you know how Abilify affects you. Abilify may make you drowsy.
  • Avoid getting over-heated or dehydrated.
    • Do not over-exercise.
    • In hot weather, stay inside in a cool place if possible.
    • Stay out of the sun. Do not wear too much or heavy clothing.
    • Drink plenty of water.

What are the possible side effects of Abilify?

Abilify may cause serious side effects, including:

  • See ” What is the most important information I should know about Abilify?”
  • Stroke in elderly people (cerebrovascular problems) that can lead to death
  • Neuroleptic malignant syndrome (NMS). Tell your healthcare provider right away if you have some or all of the following symptoms: high fever, stiff muscles, confusion, sweating, changes in pulse, heart rate, and blood pressure. These may be symptoms of a rare and serious condition that can lead to death. Call your healthcare provider right away if you have any of these symptoms.

  • Uncontrolled body movements (tardive dyskinesia). Abilify may cause movements that you cannot control in your face, tongue, or other body parts. Tardive dyskinesia may not go away, even if you stop receiving Abilify. Tardive dyskinesia may also start after you stop receiving Abilify.

  • Problems with your metabolism such as:

    • High blood sugar (hyperglycemia) and diabetes. Increases in blood sugar can happen in some people who take Abilify. Extremely high blood sugar can lead to coma or death. If you have diabetes or risk factors for diabetes (such as being overweight or a family history of diabetes), your healthcare provider should check your blood sugar before you start Abilify and during your treatment.
      Call your healthcare provider if you have any of these symptoms of high blood sugar while receiving Abilify:

      • feel very thirsty
      • need to urinate more than usual
      • feel very hungry
      • feel weak or tired
      • feel sick to your stomach
      • feel confused, or your breath smells fruity
    • Increased fat levels (cholesterol and triglycerides) in your blood.
    • Weight gain. You and your healthcare provider should check your weight regularly.

  • Unusual urges. Some people taking Abilify have had unusual urges, such as gambling, binge eating or eating that you cannot control (compulsive), compulsive shopping and sexual urges.
    If you or your family members notice that you are having unusual urges or behaviors, talk to your healthcare provider.

  • Orthostatic hypotension (decreased blood pressure). Lightheadedness or fainting may happen when rising too quickly from a sitting or lying position.

  • Falls. Abilify may make you sleepy or dizzy, may cause a decrease in your blood pressure when changing position and can slow your thinking and motor skills which may lead to falls that can cause fractures or other injuries.

  • Low white blood cell count
  • Seizures (convulsions)
  • Problems with control of your body temperature especially when you exercise a lot or are in an area that is very hot. It is important for you to drink water to avoid dehydration. See ” What should I avoid while receiving Abilify?”

  • Difficulty swallowing that can cause food or liquid to get into your lungs.

The most common side effects of Abilify in adults include:

  • nausea
  • vomiting
  • constipation
  • headache
  • blurred vision
  • upper respiratory illness
  • dizziness
  • anxiety
  • insomnia
  • restlessness
  • inner sense of restlessness/need to move (akathisia)
The most common side effects of Abilify in children include:
  • feeling sleepy
  • headache
  • vomiting
  • إعياء
  • increased or decreased appetite
  • increased saliva or drooling
  • insomnia
  • nausea
  • stuffy nose
  • weight gain
  • uncontrolled movement such as restlessness, tremor
  • muscle stiffness
These are not all the possible side effects of Abilify.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store Abilify?

  • Store Abilify at room temperature, between 68°F to 77°F (20°C to 25°C).
  • Opened bottles of Abilify Oral Solution can be used for up to 6 months after opening, but not beyond the expiration date on the bottle.

Keep Abilify and all medicines out of the reach of children.

General information about the safe and effective use of Abilify
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use Abilify for a condition for which it was not prescribed. Do not give Abilify to other people, even if they have the same symptoms you have. It may harm them. You can ask your healthcare provider or pharmacist for information about Abilify that was written for healthcare professionals.

What are the ingredients in Abilify?
Active ingredient: aripiprazole
Inactive ingredients:
Tablets: cornstarch, hydroxypropyl cellulose, lactose monohydrate, magnesium stearate, and microcrystalline cellulose. Colorants include ferric oxide (yellow or red) and FD&C Blue No. 2 Aluminum Lake
Abilify DISCMELT Orally Disintegrating Tablets: acesulfame potassium, aspartame (which contains phenylalanine), calcium silicate, croscarmellose sodium, crospovidone, crème de vanilla (natural and artificial flavors), magnesium stearate, microcrystalline cellulose, silicon dioxide, tartaric acid, and xylitol. Colorants include ferric oxide (yellow or red) and FD&C Blue No. 2 Aluminum Lake
Abilify Oral Solution: disodium edetate, fructose (200 mg per mL), glycerin, dl-lactic acid, methylparaben, propylene glycol, propylparaben, sodium hydroxide, sucrose (400 mg per mL), and purified water. The oral solution is flavored with natural orange cream and other natural flavors
For more information about Abilify go to www.Abilify.com or call 1-800-438-6055.
Tablets manufactured by Otsuka Pharmaceutical Co., Ltd., Tokyo, 101-8535 Japan
Orally Disintegrating Tablets, Oral Solution, and Injection manufactured by Bristol-Myers Squibb Company, Princeton, NJ 08543 USA
Distributed and marketed by Otsuka America Pharmaceutical, Inc., Rockville, MD 20850 USA
Abilify is a trademark of Otsuka Pharmaceutical Company.
© Otsuka Pharmaceutical Co., Ltd., Tokyo, 101-8535 Japan

PACKAGE/LABEL PRINCIPAL DISPLAY PANEL

30 Tablets NDC 59148-006-13
Abilify®
(aripiprazole)
TABLETS
2 mg
DISPENSE WITH MEDICATION GUIDE
Rx only
Otsuka America Pharmaceutical, Inc.

PACKAGE/LABEL PRINCIPAL DISPLAY PANEL

30 Tablets NDC 59148-007-13
Abilify®
(aripiprazole)
TABLETS
5 mg
DISPENSE WITH MEDICATION GUIDE
Rx only
Otsuka America Pharmaceutical, Inc.

PACKAGE/LABEL PRINCIPAL DISPLAY PANEL

30 Tablets NDC 59148-008-13
Abilify®
(aripiprazole)
TABLETS
10 mg
DISPENSE WITH MEDICATION GUIDE
Rx only
Otsuka America Pharmaceutical, Inc.

PACKAGE/LABEL PRINCIPAL DISPLAY PANEL

30 Tablets NDC 59148-009-13
Abilify®
(aripiprazole)
TABLETS
15 mg
DISPENSE WITH MEDICATION GUIDE
Rx only
Otsuka America Pharmaceutical, Inc.

PACKAGE/LABEL PRINCIPAL DISPLAY PANEL

30 Tablets NDC 59148-010-13
Abilify®
(aripiprazole)
TABLETS
20 mg
DISPENSE WITH MEDICATION GUIDE
Rx only
Otsuka America Pharmaceutical, Inc.

PACKAGE/LABEL PRINCIPAL DISPLAY PANEL

30 Tablets NDC 59148-011-13
Abilify®
(aripiprazole)
TABLETS
30 mg
DISPENSE WITH MEDICATION GUIDE
Rx only
Otsuka America Pharmaceutical, Inc.

PACKAGE/LABEL PRINCIPAL DISPLAY PANEL

1 Bottle NDC 59148-013-15
150 mL
Abilify®
(aripiprazole)
Oral Solution
1 mg/mL
DISPENSE WITH MEDICATION GUIDE
Rx only
Otsuka America Pharmaceutical, Inc.
Bristol-Myers Squibb

PACKAGE/LABEL PRINCIPAL DISPLAY PANEL

1 Vial NDC 59148-016-65
Abilify®
(aripiprazole)
INJECTION
9.75 mg/1.3 mL
(7.5 mg/mL)
DISPENSE WITH MEDICATION GUIDE
For Intramusular Use Only.
Single-use container.
Discard any unused portion.
Sterile, Ready-to-Use Solution.
Rx only
Otsuka America Pharmaceutical, Inc.
Bristol-Myers Squibb

PACKAGE/LABEL PRINCIPAL DISPLAY PANEL

30 Tablets (3 x 10) NDC 59148-640-23
Abilify DISCMELT®10 mg
(aripiprazole) Rx only
Orally Disintegrating Tablets
DISPENSE WITH MEDICATION GUIDE
Bristol-Myers Squibb
Otsuka America Pharmaceutical, Inc.

PACKAGE/LABEL PRINCIPAL DISPLAY PANEL

30 Tablets (3 x 10) NDC 59148-641-23
Abilify DISCMELT®15 mg
(aripiprazole) Rx only
Orally Disintegrating Tablets
DISPENSE WITH MEDICATION GUIDE
Bristol-Myers Squibb
Otsuka America Pharmaceutical, Inc.

Abilify
aripiprazole tablet

معلومات المنتج
نوع المنتجملصق وصف الأدوية البشريةرمز البند (المصدر)NDC:59148-006
مسار الإدارةORALجدول إدارة مكافحة المخدرات
العنصر النشط / النشأة النشطة
اسم العنصرأساس القوةقوة

ARIPIPRAZOLE (ARIPIPRAZOLE)

ARIPIPRAZOLE2 mg
مكونات غير فعالة
اسم العنصرقوة
STARCH, CORN
HYDROXYPROPYL CELLULOSE (1600000 WAMW)
LACTOSE MONOHYDRATE
MAGNESIUM STEARATE
MICROCRYSTALLINE CELLULOSE
FERRIC OXIDE RED
FERRIC OXIDE YELLOW
FD&C BLUE NO. 2
ALUMINUM OXIDE
Product Characteristics
اللونgreenScoreno score
ShapeRECTANGLE (modified rectangle)Size8mm
FlavorImprint CodeA;006;2
Contains
التعبئة والتغليف
#رمز الصنفحزمة الوصف
1NDC:59148-006-1330 TABLET in 1 BOTTLE, PLASTIC
2NDC:59148-006-927 TABLET in 1 BLISTER PACK
المعلومات التسويقية
فئة التسويقرقم الطلب أو الاستشهاد بالدراسةتاريخ بدء التسويقتاريخ انتهاء التسويق
التجمع الوطني الديمقراطيNDA02143611/15/2002

Abilify
aripiprazole tablet

معلومات المنتج
نوع المنتجملصق وصف الأدوية البشريةرمز البند (المصدر)NDC:59148-007
مسار الإدارةORALجدول إدارة مكافحة المخدرات
العنصر النشط / النشأة النشطة
اسم العنصرأساس القوةقوة

ARIPIPRAZOLE (ARIPIPRAZOLE)

ARIPIPRAZOLE5 mg
مكونات غير فعالة
اسم العنصرقوة
STARCH, CORN
HYDROXYPROPYL CELLULOSE (1600000 WAMW)
LACTOSE MONOHYDRATE
MAGNESIUM STEARATE
MICROCRYSTALLINE CELLULOSE
FERRIC OXIDE RED
FERRIC OXIDE YELLOW
FD&C BLUE NO. 2
ALUMINUM OXIDE
Product Characteristics
اللونblueScoreno score
ShapeRECTANGLE (modified rectangle)Size8mm
FlavorImprint CodeA;007;5
Contains
التعبئة والتغليف
#رمز الصنفحزمة الوصف
1NDC:59148-007-1330 TABLET in 1 BOTTLE, PLASTIC
2NDC:59148-007-35100 TABLET in 1 BLISTER PACK
3NDC:59148-007-947 TABLET in 1 BLISTER PACK
المعلومات التسويقية
فئة التسويقرقم الطلب أو الاستشهاد بالدراسةتاريخ بدء التسويقتاريخ انتهاء التسويق
التجمع الوطني الديمقراطيNDA02143611/15/2002

Abilify
aripiprazole tablet

معلومات المنتج
نوع المنتجملصق وصف الأدوية البشريةرمز البند (المصدر)NDC:59148-008
مسار الإدارةORALجدول إدارة مكافحة المخدرات
العنصر النشط / النشأة النشطة
اسم العنصرأساس القوةقوة

ARIPIPRAZOLE (ARIPIPRAZOLE)

ARIPIPRAZOLE10 mg
مكونات غير فعالة
اسم العنصرقوة
STARCH, CORN
HYDROXYPROPYL CELLULOSE (1600000 WAMW)
LACTOSE MONOHYDRATE
MAGNESIUM STEARATE
MICROCRYSTALLINE CELLULOSE
FERRIC OXIDE RED
FERRIC OXIDE YELLOW
FD&C BLUE NO. 2
ALUMINUM OXIDE
Product Characteristics
اللونpinkScoreno score
ShapeRECTANGLE (modified rectangle)Size8mm
FlavorImprint CodeA;008;10
Contains
التعبئة والتغليف
#رمز الصنفحزمة الوصف
1NDC:59148-008-1330 TABLET in 1 BOTTLE, PLASTIC
2NDC:59148-008-35100 TABLET in 1 BLISTER PACK
3NDC:59148-008-957 TABLET in 1 BLISTER PACK
المعلومات التسويقية
فئة التسويقرقم الطلب أو الاستشهاد بالدراسةتاريخ بدء التسويقتاريخ انتهاء التسويق
التجمع الوطني الديمقراطيNDA02143611/15/2002

Abilify
aripiprazole tablet

معلومات المنتج
نوع المنتجملصق وصف الأدوية البشريةرمز البند (المصدر)NDC:59148-009
مسار الإدارةORALجدول إدارة مكافحة المخدرات
العنصر النشط / النشأة النشطة
اسم العنصرأساس القوةقوة

ARIPIPRAZOLE (ARIPIPRAZOLE)

ARIPIPRAZOLE15 mg
مكونات غير فعالة
اسم العنصرقوة
STARCH, CORN
HYDROXYPROPYL CELLULOSE (1600000 WAMW)
LACTOSE MONOHYDRATE
MAGNESIUM STEARATE
MICROCRYSTALLINE CELLULOSE
FERRIC OXIDE RED
FERRIC OXIDE YELLOW
FD&C BLUE NO. 2
ALUMINUM OXIDE
Product Characteristics
اللونyellowScoreno score
ShapeROUNDSize6mm
FlavorImprint CodeA;009;15
Contains
التعبئة والتغليف
#رمز الصنفحزمة الوصف
1NDC:59148-009-1330 TABLET in 1 BOTTLE, PLASTIC
2NDC:59148-009-35100 TABLET in 1 BLISTER PACK
3NDC:59148-009-957 TABLET in 1 BLISTER PACK
المعلومات التسويقية
فئة التسويقرقم الطلب أو الاستشهاد بالدراسةتاريخ بدء التسويقتاريخ انتهاء التسويق
التجمع الوطني الديمقراطيNDA02143611/15/2002

Abilify
aripiprazole tablet

معلومات المنتج
نوع المنتجملصق وصف الأدوية البشريةرمز البند (المصدر)NDC:59148-010
مسار الإدارةORALجدول إدارة مكافحة المخدرات
العنصر النشط / النشأة النشطة
اسم العنصرأساس القوةقوة

ARIPIPRAZOLE (ARIPIPRAZOLE)

ARIPIPRAZOLE20 mg
مكونات غير فعالة
اسم العنصرقوة
STARCH, CORN
HYDROXYPROPYL CELLULOSE (1600000 WAMW)
LACTOSE MONOHYDRATE
MAGNESIUM STEARATE
MICROCRYSTALLINE CELLULOSE
FERRIC OXIDE RED
FERRIC OXIDE YELLOW
FD&C BLUE NO. 2
ALUMINUM OXIDE
Product Characteristics
اللونأبيضScoreno score
ShapeROUNDSize8mm
FlavorImprint CodeA;010;20
Contains
التعبئة والتغليف
#رمز الصنفحزمة الوصف
1NDC:59148-010-1330 TABLET in 1 BOTTLE, PLASTIC
2NDC:59148-010-35100 TABLET in 1 BLISTER PACK
المعلومات التسويقية
فئة التسويقرقم الطلب أو الاستشهاد بالدراسةتاريخ بدء التسويقتاريخ انتهاء التسويق
التجمع الوطني الديمقراطيNDA02143611/15/2002

Abilify
aripiprazole tablet

معلومات المنتج
نوع المنتجملصق وصف الأدوية البشريةرمز البند (المصدر)NDC:59148-011
مسار الإدارةORALجدول إدارة مكافحة المخدرات
العنصر النشط / النشأة النشطة
اسم العنصرأساس القوةقوة

ARIPIPRAZOLE (ARIPIPRAZOLE)

ARIPIPRAZOLE30 mg
مكونات غير فعالة
اسم العنصرقوة
STARCH, CORN
HYDROXYPROPYL CELLULOSE (1600000 WAMW)
LACTOSE MONOHYDRATE
MAGNESIUM STEARATE
MICROCRYSTALLINE CELLULOSE
FERRIC OXIDE RED
FERRIC OXIDE YELLOW
FD&C BLUE NO. 2
ALUMINUM OXIDE
Product Characteristics
اللونpinkScoreno score
ShapeROUNDSize9mm
FlavorImprint CodeA;011;30
Contains
التعبئة والتغليف
#رمز الصنفحزمة الوصف
1NDC:59148-011-1330 TABLET in 1 BOTTLE, PLASTIC
2NDC:59148-011-35100 TABLET in 1 BLISTER PACK
المعلومات التسويقية
فئة التسويقرقم الطلب أو الاستشهاد بالدراسةتاريخ بدء التسويقتاريخ انتهاء التسويق
التجمع الوطني الديمقراطيNDA02143611/15/2002

Abilify
aripiprazole solution

معلومات المنتج
نوع المنتجملصق وصف الأدوية البشريةرمز البند (المصدر)NDC:59148-013
مسار الإدارةORALجدول إدارة مكافحة المخدرات
العنصر النشط / النشأة النشطة
اسم العنصرأساس القوةقوة

ARIPIPRAZOLE (ARIPIPRAZOLE)

ARIPIPRAZOLE1 mg  in 1 mL
مكونات غير فعالة
اسم العنصرقوة
FRUCTOSE200 mg  in 1 mL
جلسيرين
LACTIC ACID, DL-
METHYLPARABEN
البروبيلين غليكول
PROPYLPARABEN
SODIUM HYDROXIDE
SUCROSE400 mg  in 1 mL
WATER
Product Characteristics
اللونScore
ShapeSize
FlavorORANGE (natural orange cream and other natural flavors)Imprint Code
Contains
التعبئة والتغليف
#رمز الصنفحزمة الوصف
1NDC:59148-013-15150 mL in 1 BOTTLE
المعلومات التسويقية
فئة التسويقرقم الطلب أو الاستشهاد بالدراسةتاريخ بدء التسويقتاريخ انتهاء التسويق
التجمع الوطني الديمقراطيNDA02171312/10/2004

Abilify
aripiprazole tablet, orally disintegrating

معلومات المنتج
نوع المنتجملصق وصف الأدوية البشريةرمز البند (المصدر)NDC:59148-640
مسار الإدارةORALجدول إدارة مكافحة المخدرات
العنصر النشط / النشأة النشطة
اسم العنصرأساس القوةقوة

ARIPIPRAZOLE (ARIPIPRAZOLE)

ARIPIPRAZOLE10 mg
مكونات غير فعالة
اسم العنصرقوة
ACESULFAME POTASSIUM
ASPARTAME
CALCIUM SILICATE
CROSCARMELLOSE SODIUM
CROSPOVIDONE (15 MPA.S AT 5%)
MAGNESIUM STEARATE
MICROCRYSTALLINE CELLULOSE
SILICON DIOXIDE
TARTARIC ACID
XYLITOL
FD&C BLUE NO. 2
ALUMINUM OXIDE
PHENYLALANINE1.12 mg
Product Characteristics
اللونpink (pink with scattered specks)Scoreno score
ShapeROUNDSize7mm
FlavorVANILLA (crème de vanilla (natural and artificial flavors))Imprint CodeA;640;10
Contains
التعبئة والتغليف
#رمز الصنفحزمة الوصف
1NDC:59148-640-2330 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK
المعلومات التسويقية
فئة التسويقرقم الطلب أو الاستشهاد بالدراسةتاريخ بدء التسويقتاريخ انتهاء التسويق
التجمع الوطني الديمقراطيNDA02172906/07/2006

Abilify
aripiprazole tablet, orally disintegrating

معلومات المنتج
نوع المنتجملصق وصف الأدوية البشريةرمز البند (المصدر)NDC:59148-641
مسار الإدارةORALجدول إدارة مكافحة المخدرات
العنصر النشط / النشأة النشطة
اسم العنصرأساس القوةقوة

ARIPIPRAZOLE (ARIPIPRAZOLE)

ARIPIPRAZOLE15 mg
مكونات غير فعالة
اسم العنصرقوة
ACESULFAME POTASSIUM
ASPARTAME
CALCIUM SILICATE
CROSCARMELLOSE SODIUM
CROSPOVIDONE (15 MPA.S AT 5%)
MAGNESIUM STEARATE
MICROCRYSTALLINE CELLULOSE
SILICON DIOXIDE
TARTARIC ACID
XYLITOL
FD&C BLUE NO. 2
ALUMINUM OXIDE
PHENYLALANINE1.68 mg
Product Characteristics
اللونyellow (yellow with scattered specks)Scoreno score
ShapeROUNDSize8mm
FlavorVANILLA (crème de vanilla (natural and artificial flavors))Imprint CodeA;641;15
Contains
التعبئة والتغليف
#رمز الصنفحزمة الوصف
1NDC:59148-641-2330 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK
المعلومات التسويقية
فئة التسويقرقم الطلب أو الاستشهاد بالدراسةتاريخ بدء التسويقتاريخ انتهاء التسويق
التجمع الوطني الديمقراطيNDA02172906/07/2006

Abilify
aripiprazole injection, solution

معلومات المنتج
نوع المنتجملصق وصف الأدوية البشريةرمز البند (المصدر)NDC:59148-016
مسار الإدارةINTRAMUSCULARجدول إدارة مكافحة المخدرات
العنصر النشط / النشأة النشطة
اسم العنصرأساس القوةقوة

ARIPIPRAZOLE (ARIPIPRAZOLE)

ARIPIPRAZOLE9.75 mg  in 1.3 mL
مكونات غير فعالة
اسم العنصرقوة
BETADEX SULFOBUTYL ETHER SODIUM
TARTARIC ACID
SODIUM HYDROXIDE
التعبئة والتغليف
#رمز الصنفحزمة الوصف
1NDC:59148-016-651.3 mL in 1 VIAL
المعلومات التسويقية
فئة التسويقرقم الطلب أو الاستشهاد بالدراسةتاريخ بدء التسويقتاريخ انتهاء التسويق
التجمع الوطني الديمقراطيNDA02186609/20/2006

Labeler – Otsuka America Pharmaceutical, Inc. (008314390)

Registrant – Bristol-Myers Squibb Company (102826703)

Otsuka America Pharmaceutical, Inc.

Related questions

.

Leave A Reply

Your email address will not be published.